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background: the ewing sarcoma family 
of tumors (ESFT) are rare but highly 
malignant neoplasms that occur mainly in 
bone or but also in soft tissue. ESFT affects 
patients typically in their second decade of 
life, whereby children and adolescents bear 
the heaviest incidence burden. Despite recent 
advances in the clinical management of ESFT 
patients, their prognosis and survival are still 
disappointingly poor, especially in cases with 
metastasis. No targeted therapy for ESFT 
patients is currently available. Moreover, 
based merely on current clinical and biological 
characteristics, accurate classification of 
ESFT patients often fails at the time of 
diagnosis. Therefore, there is a constant need 
for novel molecular biomarkers to be applied 
in tandem with conventional parameters to 
further intensify ESFT risk-stratification and 
treatment selection, and ultimately to develop 
novel targeted therapies. In this context, a 
greater understanding of the genetics and 
immune characteristics of ESFT is needed.
Aims This study sought to open novel 
insights into gene copy number changes and 
gene expression in ESFT and, further, to 
enlighten the role of inflammation in ESFT. 
For this purpose, microarrays were used to 
provide gene-level information on a genome-
wide scale. In addition, this study focused 
on screening of 9p21.3 deletion sizes and 
frequencies in ESFT and, in another pediatric 
cancer, acute lymphocytic leukemia (ALL), in 
order to define more exact criteria for high-
risk patient selection and to provide data for 
developing a more reliable diagnostic method 
to detect CDKN2A deletions.
Results In study I, 20 novel ESFT-associated 
suppressor genes and oncogenes were 
pinpointed using combined array CGH and 
expression analysis. In addition, interesting 
chromosomal rearrangements were identified: 
(1) Duplication of derivative chromosome 
der(22)(11;22) was detected in three ESFT 
patients. This duplication included the 
EWSR1-FLI1 fusion gene leading to increase 
in its copy number; (2) Cryptic amplifications 
on chromosomes 20 and 22 were detected, 
suggesting a novel translocation between 
chromosomes 20 and 22, which most probably 
produces a fusion between EWSR1 and 
NFATC2. 
In study II, bioinformatic analysis of 
ESFT expression profiles showed that inflam-
Abstract
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matory gene activation is detectable in ESFT 
patient samples and that the activation is 
characterized by macrophage gene expression. 
Most interestingly, ESFT patient samples were 
shown to express certain inflammatory genes 
that were prognostically significant. High local 
expression of C5 and JAK1 at the tumor site 
was shown to associate with favorable clinical 
outcome, whereas high local expression of IL8 
was shown to be detrimental.
Studies III and IV showed that the 
smallest overlapping region of deletion in 
9p21.3 includes CDKN2A in all cases and that 
the length of this region is 12.2 kb in both 
Ewing sarcoma and ALL. Furthermore, our 
results showed that the most widely used com-
mercial CDKN2A FISH probe creates false 
negative results in the narrowest microdele-
tion cases (<190 kb). Therefore, more accurate 
methods should be developed for the detection 
of deletions in the CDKN2A locus.
Conclusions This study provides novel insights 
into the genetic changes involved in the 
biology of ESFT, in the interaction between 
ESFT cells and immune system, and in 
the inactivation of CDKN2A. Novel ESFT 
biomarker genes identified in this study serve 
as a useful resource for future studies and in 
developing novel therapeutic strategies to 
improve the survival of patients with ESFT. 
Key words Ewing sarcoma family of tumors, 
pediatric cancers, CDKN2A, microarray, gene 
copy number, gene expression, inflammation, 
prognostic factor
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ewingin sarkooma on pahanlaatuinen 
luukasvain, jota esiintyy sen harvinaisuudesta 
huolimatta etenkin lapsilla ja murrosikäisillä. 
Ewingin sarkoomalle ominainen piirre on 
kromosomien 11 ja 22 välinen uudelleen-
järjestäytyminen eli translokaatio, joka johtaa 
kimeerisen EWSR1-FLI1 -fuusiogeenin syn-
tymisen ja muuttuneen geenien ilmentymisen 
kautta solujen pahanlaatuistumiseen. Koska 
kasvain lähettää aggressiivisesti etäpesäkkeitä, 
jää potilaiden eloonjääntiluku alhaiseksi uu-
sista yhdistelmähoidoista huolimatta. Kun 
edelleenkään ei tunneta tarkkoja syitä näiden 
luukasvainten kehittymiselle ja etenemiselle, 
on potilaiden hoito haastavaa eikä tarpeeksi 
tehokasta ja spesifistä hoitoa ole annettavissa. 
Tämän takia tarve uusien kliinisesti merkittä-
vien kohdegeenien löytymiselle Ewingin sar-
koomassa on suuri, jotta taudin diagnosointi 
ja ennusteen määrittäminen helpottuisi sekä 
uusien kohdennettujen hoitomuotojen kehit-
täminen mahdollistuisi.
Tutkimuksessa käytettiin mikro-
sirupohjaisia menetelmiä geenien kopiomäärän 
ja ilmentymisen muutosten kartoittamiseen 
koko perimän laajuisesti kliinisesti merkittä-
vien kohdegeenien ja geneettisten muutosten 
löytämiseksi Ewingin sarkoomassa. Lisäksi 
mikrosirumenetelmää hyödynnettiin kasvu-
rajoitegeeni-CDKN2A:n häviämien tutki-
misessa, jotta saataisiin tietoa geenin häviämien 
koosta ja yleisyydestä Ewingin sarkoomassa 
sekä toisessa lasten syövässä, akuutissa lym-
faattisessa leukemiassa (ALL).
Ensimmäisessä osatyössä saimme 
tarkempaa tietoa mahdollisista Ewingin 
sarkooma-kasvaimen kehitykseen johtavista 
geneettisistä muutoksista yhdistämällä 
geenien kopiomäärä- ja ilmentymisprofiilit 
potilasnäytteissä. Tutkimuksemme osoitti 20 
uutta potentiaalista onkogeeniä ja kasvu-
rajoitegeeniä, jotka voivat osallistua kasvaimen 
kehittymiseen ja etenemiseen. Geenien kopio-
määrätutkimuksessa havaitsimme kolmessa 
potilasnäytteessä myös derivatiivikromosomin 
der(22)(11;22) kahdentuman seurauksena 
EWSR1-FLI1 -fuusiogeenin kopiomäärän 
lisääntymisen. Lisäksi yhdessä potilasnäyt-
teessä havaittiin korkea-asteisia kromosomien 
20 ja 22 monistumia, jotka viittaavat translo-
kaatioon EWSR1- ja NFATC2-geenien välillä.
Toisessa osatyössä tutkimme Ewingin 
sarkoomakasvainten ja niitä ympäröivien ku-
dosten välistä vuorovaikutusta analysoimalla 
tulehdukseen liittyvien geenien ilmentymistä. 
Tutkimuksessamme havaittiin tilastollisesti 
Tiivistelmä
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merkittävä tulehduksellisten geenien ilmen-
tymisen lisääntyminen Ewingin sarkoomapo-
tilasnäytteissä. Näytteistä voitiin todeta myös 
merkittävä makrofaagigeenien aktivoitu-
minen. Mielenkiintoisimpana tuloksena tut-
kimuksemme osoitti komplementtitekijä C5:n 
paikallisen ilmentymisen vaikuttavan Ewingin 
sarkoomapotilaiden eloonjääntiin annosvasteesta 
riippuen. Tietääksemme tutkimuksemme on 
ensimmäinen, joka yhdistää komplementtitekijä 
C5:n ilmentymisen potilaiden eloonjääntiin mis-
sään syöpätyypissä. Komplementti on elimistön 
yleiseen immuunivasteeseen kuuluva puolus-
tusjärjestelmä, jonka tarkoituksena on tuhota 
elimistölle vieraita tai muuntuneita soluja ja 
tehostaa adaptiivisen immuunivasteen toimintaa.
Kolmannessa ja neljännessä osatyössä 
kartoitimme kromosomiraidan 9p21.3 
häviämien koon ja yleisyyden sekä Ewingin 
sarkooma- että ALL-näytteissä. Totesimme, 
että kaikkien havaittujen 9p21.3-häviäminen 
pienin yhteinen alue sisältää CDKN2A-
geenin ja että se on noin 12.2 kiloemästä 
pitkä sekä Ewingin sarkoomassa että ALL:ssa. 
Tutkimuksemme perusteella voidaankin 
todeta, että yleisimmin käytetyt kaupalliset 
FISH-koettimet CDKN2A-poikkeamien analy-
soinnissa tuottavat vääriä negatiivisia tuloksia 
pienimpien CDKN2A-häviämien osalta.
Uusien kohdegeenien ja ennusteellisten 
tekijöiden tunnistamisen myötä tutkimuk-
semme mahdollistaa entistä tarkemman 
diagnoosin ja tehokkaampien hoitomuotojen 
kehittämisen Ewingin sarkoomaan. Lisäksi 
tutkimuksemme tuotti arvokasta tietoa 
CDKN2A-geenin häviämien koosta sekä 
yleisyydestä Ewingin sarkoomassa ja ALL:ssa, 
minkä perusteella voitaisiin kehittää entistä 
tarkempi menetelmä CDKN2A-häviämien 
havainnointiin potilasnäytteistä.
Avainsanat Ewingin sarkooma, lasten syövät, 
CDKN2A, mikrosirut, geenien kopiomäärä, 
geenien ilmentyminen, tulehdusreaktiot, en-
nusteelliset tekijät
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cancer is a highly complex disease 
caused by abnormal cell proliferation or lack 
of apoptosis combined with invasive behavior 
and metastasis. At cellular level, cancer can be 
regarded as a genetic disease, since somatic 
and, more rarely, germline aberrations in 
the genome are the hallmark of all human 
cancers (ponder 2001). Cancer cells can 
present a variety of genomic alterations: e.g., 
structural chromosomal rearrangements, more 
subtle mutations in the sequence, epigenetic 
changes or changes in miRNA expression 
(Figure 1). These aberrations can be either 
inherited or spontaneously acquired when 
a normal cell becomes malignant. Most 
importantly, the genetic changes in cancer 
cells typically activate target pathways and 
biological networks that contribute to cancer 
pathogenesis (vogelstein and kinzler, 
2004). On the other hand, certain pathways 
and genes encoding proteins, which in normal 
cell conditions serve as brakes on cell growth 
and proliferation, can be inactivated in 
malignant cells, for example tumor suppressor 
gene CDKN2A. Consequently, cancer 
phenotype is a result of multiple interactive and 
synergistic pathways in each individual tumor 
cell as well as between tumor cells and the 
surrounding tissues of the host. The interplay 
between cancerous cells and the host can 
trigger inflammatory reactions. Particularly in 
carcinomas, the tumor microenvironment can 
closely resemble an inflammation site, which 
can promote tumor progression, especially 
when combined with immunosuppression 
(vakkila and lotze, 2004). At the same 
time, growing evidence shows that both innate 
and adaptive immune systems can recognize 
nascent tumors and actively fight against 
them, which can ultimately lead to complete 
remission.
Comprehensive characterization of 
the genetic changes associated with tumori-
genesis and malignant behavior is crucial for 
pinpointing novel target genes, which will pre-
pare the way for future advances in therapeutic 
interventions. This applies to all neoplasias, 
 including the Ewing sarcoma family of tumors. 
In addition, knowledge of genetic changes, 
which are necessary for ESFT progression, 
makes it possible to define markers or signa-
tures that can predict prognosis or therapeutic 
response. Novel tools, such as microarray-based 
applications, can survey thousands of genes 
simultaneously and provide measurements 
of the genetic alterations on a genome-wide 
Introduction
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scale both at gene expression and copy number 
 levels. Moreover, to enhance the understanding 
of molecular pathways involved in ESFT cells, 
integration of both gene expression and copy 
number data can facilitate the identification of 
key cellular pathways and, moreover, assist in 
candidate gene discovery.
The fundamental goal of the present 
study is to improve the diagnosis and therapy 
of ESFT patients through more precise 
knowledge of genes involved in the tumori-
genesis and tumor progression, which will 
enable design of treatments that are more pre-
cisely targeted to this particular cancer type. 
Moreover, as defects of CDKN2A are involved 
in tumor formation in various tissue types 
and associated with more aggressive course of 
disease, accurate characterization of CDKN2A 
aberrations is crucial for more accurate clas-
sification of patients with favorable and poor 
prognosis. Accordingly, a better understanding 
of the molecular bases of ESFT pathogenesis 
and CDKN2A aberrations is vital and likely to 
produce clinical benefits in the near future.
Figure 1. Genetic alterations in cancer
(A) Structural chromosomal rearrangements, (B) mutations in DNA sequences, and (C) epigenetic and microRNA (miRNA) 
changes are seen in the genome of cancer cells. Figure 1A is reprinted from www.genome.gov/glossary.cfm and used with 
permission from National Human Genome Research Institute.
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1 Ewing sarcoma family of tumors (ESFTs)
Ewing sarcoma was first described in 1921 by 
James Ewing (ewing, 1921), who named this 
tumor “diffuse endothelioma of bone”. Based on 
the form of cells, he thought that this tumor 
is endothelial and postulated that it originates 
from the blood vessels of the bone tissue. Since 
then several nomenclatures have been applied, 
but in 2002 the World Health Organization 
settled on naming the entire tumor entity 
Ewing sarcoma/Primitive neuroectodermal 
tumor (flecher et al., 2002). The Ewing 
sarcoma family of tumors can be divided into 
four subtypes: (1) classical Ewing sarcoma of 
bones, (2) extraskeletal Ewing sarcoma of soft 
tissues, (3) primitive neuroectodermal tumor 
(PNET), and (4) Askin tumor, according 
to their primary site and histopathological 
features (crist and kun, 1991; pizzo 
and poplack, 2002). The cell of origin 
in ESFT has been and still is a matter of 
debate. Histologically, the degree of neural 
differentiation in PNET and Askin tumor is 
higher than in classical and extraskeletal Ewing 
sarcoma. Whereas ESFT cells show variable 
degrees of neuroectodermal differentiation 
and verifiably express certain neural markers 
suggesting their neuroectodermal origin 
(cavazzana et al., 1987; lizard-nacol et 
al., 1989), more recent in vitro and in silico 
studies clearly suggest that ESFT originates 
from mesechymal stem cells (MSC) (tirode 
et al., 2007; potikyan et al., 2008; kauer 
et al., 2009). 
1.1 Clinical characteristics of ESFTs
ESFTs are rare but highly malignant tumors 
arising either in bone or, less frequently, in soft 
tissue. Despite its rarity, it is still the second 
most common primary bone sarcoma type in 
children and young adults after osteosarcoma 
(ries et al., 1999). The highest peak of 
incidence in ESFT is between ages 10 to 20, 
and patients are hardly ever older than 40 years 
(pieper et al., 2008), although isolated cases 
of primary ESFT in geriatric patients have 
been reported (cheung et al., 2001). The 
median age at diagnosis is ~14 years, the annual 
incidence of ESFT is 2.9 cases per million 
children under 19 years of age, and there is 
a slight male predominance, with a male to 
female ratio of 1.4 - 1.9 to 1 (cotterill et 
al., 2000; esiashvili et al., 2008). In Finland, 
the annual number of new ESFT cases ranges 
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between five and eight (joensuu et al., 2007). 
The primary tumor occurs most frequently 
(>50%) in the long bones of lower and upper 
extremities, or axially, for example in the pelvis 
(cotterill et al., 2000). Nonetheless, any 
bone or extraskeletal tissue may be affected. 
The most frequent clinical presentation is local 
tenderness or persistent pain, swelling of the 
affected area with impairment of function, 
combined sometimes with fever, weight loss, 
and fatigue. Infrequently, a ESFT patient 
with lesion of the long bones may present a 
pathologic fracture as the initial reason for 
diagnostic consultation.
ESFTs are aggressive tumors: 20-30% 
of patients have clinically evident metastases 
at the time of diagnosis (cotterill et al., 
2000; esiashvili et al., 2008). metastasis 
occurs most frequently in the lung, bone, and 
bone marrow through hematogenous spread. 
Histologically ESFTs belong to small round 
blue cell tumors, which is a descriptive catego-
ry of various malignant tumors, most of which 
occur in childhood (lessnick et al., 2009). 
Small round blue cell tumors include, e.g., 
Ewing sarcoma/PNET, neuroblastoma, rhab-
domyosarcoma, desmoplastic small round cell 
tumor, and Wilm’s tumor. Ultrastructurally, in 
hematoxylin-eosin stained sections, the cellular 
nature of ESFT cells is primitive with round 
tightly packed nuclei and scanty cytoplasm 
containing foci of cytoplasmic glycogen and 
rare cell organelles (see Figure 2 for histology 
of ESFTs).
The immunohistochemical hallmark of 
ESFT is consistent expression of cell surface 
antigen CD99 (kovar et al., 1990;  fellinger 
et al., 1991; perlman et al., 1994), which can 
be used in the differential diagnosis of ESFT. 
However, immunohistochemical positivity of 
CD99 does not exclusively distinguish ESFTs 
from other small round blue cell tumors or 
from other solid tumors, since heterogeneous 
positivity for CD99 is detected in a variety 
of tumors, e.g., lymphomas, neuroblastomas, 
osteosarcomas, rhabdomyosarcomas, osteo-
blastomas, and chondrosarcomas (fellinger 
et al., 1991; scotlandi et al., 1996; lucas 
et al., 2001). CD99 is coded by the MIC2 
gene and it is normally expressed in T cells 
(gelin et al., 1989) and B cells (dworzak 
et al., 1999). Other immunohistochemical 
markers that are variably expressed in ESFTs 
are vimentin (lucas et al., 2001), cytokeratin 
(collini et al., 2001), and FLI1 (folpe et 
al., 2000).
Figure 2. Histologic features of Ewing sarcoma family of tumors. 
Ewing sarcoma cells have a poorly differentiated cell structure and blue round nucleus with hematoxylin-eosin staining. 
(A) ESFT patient sample with invasive behavior, vital tumor cells surround myofibrils (x10). (B) Mitotically active tumor 
cells are seen with greater magnification (x20). This picture was kindly provided by Maarit Sarlomo-Rikala. 
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1.2 Treatment and prognostic factors of ESFTs
Due to its aggressive nature and early 
systematic spread, treatment of EFST is highly 
challenging. Effective management of ESFT 
patients requires both local and systemic 
therapies, because 20 to 30% of patients 
diagnosed with localized tumor actually have 
micrometastases (pfleiderer et al., 1995; 
west et al., 1997), which are undetectable 
and therefore subclinical by current routine 
procedures. In fact, before systemic therapy 
was administered, >90% of EFST patients 
died despite local tumor control within the 
first years from diagnosis. Local therapy 
consists of surgery, depending on the location 
and extent of the tumor, or radiation therapy, 
or both, since ESFT is a radiosensitive tumor 
(thacker et al., 2005). In the 1970s, systemic 
therapy was introduced and given to patients 
before and after surgery as neoadjuvant and 
adjuvant chemotherapy. Chemotherapy 
is directed to eliminate tumor cells and 
micrometastases throughout the body and it 
typically consists of a combination of different 
chemotherapeutic agents, e.g., doxorubicin, 
cyclophosphamide, ifosfamide, etoposide, and 
vincristine (thacker et al., 2005). Due to 
advances in multidisciplinary treatments and 
novel approaches of radiation, surgical, and 
chemotherapies in patient management, ESFT 
patient survival has improved significantly. The 
5-year survival of ESFT patients has increased 
from 44% to 68% over the past decade 
according to National Cancer Institute’s 
Surveillance, Epidemiology and End Results 
(SEER) Program (esiashvili et al., 2008). 
In addition, the 5-year survival of metastatic 
disease at diagnosis has increased from 16% to 
39% from 1993 to 2004 (esiashvili et al., 
2008), although it is still disappointingly low. 
Several studies have shown that chemotherapy 
induced necrosis in the tumor is one of the 
most important prognostic criteria for patient 
survival (picci et al., 1997; wunder et al., 
1998). The absence of metastases at the time 
of diagnosis (terrier et al., 1996), small 
tumor volume (<200 ml) (paulussen et al., 
2001), good response to chemotherapy (picci 
et al., 1997), primary tumor site other than 
pelvis (craft et al., 1997), and low age (<10 
years) at the time of diagnosis (grier et al., 
2003) have been shown to correlate with 
better clinical outcome. Although aggressive 
treatment has improved the clinical outcome 
in ESFT, recent protocols with higher 
cumulative doses and increased intensities 
of chemotherapy and radiation can cause 
more severe acute and chronic side effects to 
ESFT patients, e.g., bacterial infections, pains, 
malnutrition, stomatitis, hair loss, nausea, 
and vomiting. Moreover, ESFT patients 
treated with current treatment protocols have 
an increased risk for developing secondary 
malignancies, e.g., leukemias and solid tumors 
like radiation-induced osteosarcomas (bacci 
et al., 2005; navid et al., 2008). Accordingly, 
efforts should be made to minimize the doses 
of chemotherapeutic agents and radiation. 
In addition, attempts to identify markers of 
low-risk patients, who could achieve the same 
outcome with less aggressive treatment, should 
remain a priority. 
1.3 Genetic features of ESFTs
All malignant tumors are believed to arise 
and progress because of genetic alterations 
that affect normal cellular functions like 
proliferation, apoptosis, and genomic stability, 
and further enable neovascularization, tumor 
cell invasion, and metastasis (hanahan and 
weinberg, 2000). In human solid tumors, 
several factors can result in altered gene 
function: e.g., changes in gene structure and 
copy number, point mutations, or epigenetic 
modifications (albertson et al., 2003). 
In ESFT, genetic alterations seen at the 
cytogenetic level are usually simple, but both 
structural and numerical aberrations exist. 
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Interestingly, there seems to be some kind of 
genetic predisposition in the etiology of ESFT, 
since it is extremely uncommon in children 
of African or Asian origin as compared with 
children of Caucasian origin (fraumeni and 
glass, 1970; li et al., 1980; parkin et al., 
1993). According to epidemiological studies 
of pediatric patients in the United States, 
white children have a 6-fold increase in risk 
of developing Ewing sarcoma as compared 
with African-American children (ries et 
al., 1999). Moreover, a even more dramatic 
statistically significant racial difference in 
the incidence of ESFT was reported in a 
recent population-based study, which showed 
that incidence of ESFT in Caucasians was 
9-fold as compared with African Americans 
(jawad et al., 2009). In sharp contrast, other 
common bone tumors like osteosarcoma show 
a relatively equal racial distribution. So far 
the predisposing factor for ESFT in white 
children is not known, but it could putatively 
be either a copy number variation (CNV), 
single nucleotide polymorphism (SNP), or 
an epigenetic pattern that makes this ethnic 
line more prone to the development of ESFT 
(see also Figure 3). Another possibility is 
that African and Asian populations have an 
unknown protective genetic factor against 
ESFT initiation. The true explanation behind 
this phenomenon remains open and under 
dispute until novel evidence emerges.
1.3.1 Translocations in ESFTs
Initially the diagnosis of ESFTs was solely 
dependent upon radiological assessment 
of patients together with histological and 
biochemical analysis of tumor biopsies. Both 
the discovery of a nonrandom translocation 
between chromosomes 11 and 22 in the early 
80s (aurias et al., 1984; turc-carel et 
al., 1984) and, in the early 90s, identification 
of exact gene partners involved in the 
translocation, which generates the chimeric 
EWSR1-FLI1 fusion gene (Delattre et al., 
1992), have greatly facilitated the diagnosis of 
this tumor entity. Notably, the rearrangement 
generating the EWSR1-FLI1 fusion gene was 
the first translocation that was characterized 
at the molecular level in sarcomas. Variant 
translocations have also been described 
between EWSR1 on chromosomal band 
22q12 and other ETS gene family members 
(see Table 1 for details and references). 
The ETS (E26 Transformation Specific) 
transcription factor family is identified by 
an evolutionary highly conserved helix-turn-
helix DNA binding sequence, and it comprises 
~30 family members of transcription activators 
and inhibitors (sharrocks, 2001).  
The most common translocation detect-
ed in ESFTs is a rearrangement between chro-
mosomes 11 and 22, which leads to EWSR1-
FLI1 gene fusion. It is present in more than 
80% of ESFT cases. Other more rare variants 
include EWSR1 fusion to ERG, ETV1, ETV4, 
FEV, and ZNF278 (see Table 1 for details). 
The majority of these variant translocations 
are extremely rare: they are found in less than 
1% of the cases. EWSR1-ERG is an exception 
occurring in 5-10% of ESFT cases. Another 
level of complexity to the molecular genetics of 
Ewing sarcoma is added by findings that two 
ETS gene members, ERG and FEV, can fuse 
to the TET (Ten-Eleven Translocation) gene 
family member FUS leading to FUS-ERG and 
FUS-FEV gene fusions (shing et al., 2003; 
ng et al., 2007). Identification of the above 
mentioned translocations in different subtypes 
of ESFT is the evidence of their common 
histogenesis and underlines the fact that they 
all belong to the same tumor family. There are 
no reports of significant differences in clinical 
phenotypes of ESFT patients with different 
translocation types (ginsberg et al., 1999) 
and, despite structural differences in fusion 
genes, they seem to similarly induce cellular 
transformation and accelerate tumorigenesis 
(thompson et al., 1999). However, it is dif-
21
ficult to acquire sufficiently large sample sets 
to properly evaluate the clinical and biological 
impact of these rare variant translocations on 
ESFT tumor behavior and patient survival.
The EWSR1 fusion partner provides a 
strong promoter with a transactivation do-
main and the FLI1 fusion partner contributes 
with a DNA binding domain (DBD) giving 
target specificity to the transcriptional activa-
tion (may et al., 1993a). The EWSR1-FLI1 
fusion product is an aberrant chimeric tran-
scription factor, which has oncogenic proper-
ties to enable Ewing sarcoma tumorigenesis 
by inappropriately modulating downstream 
target genes and signaling pathways (may et 
al., 1993b). The EWSR1-FLI1 protein has 
been shown to bind preferentially to micro-
satellites containing more than nine GGAA 
repeats.  Thus it regulates the transcription 
of genes that contain these repeats in their 
regulatory sequences (gangwal et al., 2008; 
guillon et al., 2009). Therefore, interest-
ingly, polymorphisms in GGAA-containing 
microsatellites might contribute to differences 
in susceptibility between individuals and eth-
nic groups (gangwal and lessnick, 2008). 
The knockdown of EWSR1-FLI1 with 
small interfering RNA (siRNAs) has been 
shown to reduce growth of ESFT cells by 
decreasing cell proliferation and by increasing 
apoptosis (kovar et al., 1996; tanaka et 
al., 1997). Inhibition of EWSR1-FLI1 with 
small hairpin RNA seems to enable ESFT cell 
recovery into mesenchymal stem cell (MSC) 
phenotype and plasticity (tirode et al., 2007) 
and, moreover, EWSR1-FLI1 expression has 
been shown to trigger a gene expression profile 
in human MSCs that resembles strikingly that 
of ESFT cells (riggi et al., 2008). Together, 
these observations suggest that MSCs are the 
candidate cells from which ESFT cells origi-
nate and that the EWSR1-FLI1 fusion product 
both inhibits mesenchymal differentiation and 
promotes the neuroectodermal differentiation 
program. In addition, based on these results 
it seems that the EWSR1-EST fusion is the 
 exclusive initiating factor for the pathogen-
esis of ESFT. Although ESFT patients have 
similar clinical characteristics, breakpoint 
variability and translocation partner diver-
sity produce heterogeneity in the size of the 
 fusion product and possibly also its function. 
EWSR1-FLI1 fusion type 1 (EWSR1 exons 
1-7 fused to FLI1 exons 6-9), which is seen in 
~80% of the cases, has been shown to associate 
with  better event-free and overall survival than 
other EWSR1-FLI1 fusion variants (de alava 
et al., 1998). However, it is not certain that 
this applies to all patients or solely to patients 
with localized disease at diagnosis (zoubek et 
al., 1996; de alava et al., 1998). Larger pro-
spective clinical studies are required to clarify 
the prognostic significance of these different 
translocations and fusion types. 
In diagnostics, different translocations 
in ESFT can be identified by conventional 
Table 1. Recurrent chromosomal translocations in ESFTs
Translocation Fusion gene Type of fusion gene Prevalence Reference
t(11;22)(q24;q12) EWSR1-FLI1 Transcription factor 80-90% (delattre et al., 1992)
t(21;22)(q22;q12) EWSR1-ERG Transcription factor 5-10% (zucman et al., 1993)
t(7;22)(p22;q12) EWSR1-ETV1 Transcription factor rare (jeon et al., 1995)
t(17;22)(q12;q12) EWSR1-ETV4 Transcription factor rare (kaneko et al., 1996)
t(2;22)(q33;q12) EWSR1-FEV Transcription factor rare (peter et al., 1997)
t(1;22)(p36;q12) EWSR1-ZNF278 Transcription factor rare (mastrangelo et al., 2000)
t(16;21)(p11;q22) FUS-ERG Transcription factor rare (shing et al., 2003)
t(2;16)(q35;p11) FUS-FEV Transcription factor rare (ng et al., 2007)
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karyotyping, although sensitivity and speci-
ficity of detection is substantially enhanced 
and facilitated using fluorescent in situ 
 hybridization (FISH) (taylor et al., 
1993) and reverse transcriptase polymerase 
chain reaction (RT-PCR) (meier et al., 
1998; peter et al., 2001). Two testing strate-
gies using FISH technology have been applied 
to ESWR1-ETS fusion detection: (1) fusion 
and (2) break-apart strategy. The advantage of 
fusion FISH strategy is that it identifies the 
ETS partner gene. On the other hand, it is 
easier to interpret break-apart test results than 
the outcome of fusion approach, especially 
since a vast majority of ESFT-related trans-
locations involve a split-up of the EWSR1 
gene. However, it should be  underlined that 
also other tumors have EWSR1 rearrange-
ments, e.g., desmo plastic round cell tumors 
with EWSR1-WT1 and EWSR1-ERG fusions 
(ladanyi and gerald, 1994; ordi et al., 
1998), clear cell sarcomas with EWSR1-ATF1 
and EWSR1-CREB1 fusions (zucman et 
al., 1993; antonescu et al., 2006), myx-
oid chondrosarcomas with EWSR1-NR4A3 
fusion ( labelle et al., 1995), myxoid 
liposarcomas with EWSR1-DDIT3 fusion 
(panagopoulos et al., 1996), angiomatoid 
fibrous histiocytomas with EWSR1-ATF1 
and EWSR1-CREB1 fusions (hallor et al., 
2005; antonescu et al., 2007), and undiffer-
entiated bone sarcomas with EWSR1-POU5F1 
and EWSR1-SP3 fusions (yamaguchi et al., 
2005; wang et al., 2007). The break-apart 
FISH strategy can thus lead to a false posi-
tive result also in tumors other than ESFT, 
which is why integrated molecular diagnostics 
are essential within this tumor entity. Recent 
studies have shown that, in comparison with 
more widely used RT-PCR strategies, FISH 
is more sensitive and specific in EWSR1-ETS 
fusion detection at initial diagnosis (bridge 
et al., 2006). RT-PCR, however, seems to be 
at its best in the detection of minimal residual 
disease and in early diagnosis of recurrence. 
1.3.2 Secondary genetic alterations in ESFTs
Although translocation of ETS genes to 
EWSR1 or, more uncommonly, to FUS, seems 
to be the initial genetic alteration in ESFT, 
it is important to consider that this balanced 
translocation is seldom the sole genetic 
anomaly. Through clonal evolution secondary 
genetic changes frequently accumulate in the 
tumor genome and they are likely to have 
an important role in providing additional 
growth advantage and, further, in allowing the 
metastatic behavior of tumor cells (boland 
and goel, 2005) (see also Figure 3). Moreover, 
these secondary genetic aberrations typically 
involve genes that regulate cell proliferation 
Figure 3. A multistep model for accumulation of genetic aberrations, enabling the development of ESFT. 
Tumorigenesis of ESFT is presumably a gradual process in which clustering of numerous genetic changes leads to the 
transformation of a normal cell into a malignant cell, which is able to metastasize. Metastasis in ESFTs most often affects 
lungs, bones, or bone marrow, but seldom lymph nodes, which are frequently affected in other tumor entities.
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and apoptosis, i.e., oncogenes and tumor 
suppressor genes, and thereby contribute to 
malignant progression of cancer cells.
Secondary genetic changes are detected 
in around 80% of Ewing sarcoma tumors at 
the time of diagnosis (zielenska et al., 2001; 
roberts et al., 2008). The most common 
secondary cytogenetic alterations in ESFT are 
gains of 1q, 8, and 12, and losses of 9p21.3 and 
16q. Most of these alterations have been asso-
ciated with adverse clinical outcome in EFTS 
patients, including the gain of 1q (hattinger 
et al., 2002), deletion of 1p36 (hattinger 
et al., 1999), loss of 9p21.3 (including loss of 
CDKN2A) (huang et al., 2005), and loss of 
16q (hattinger et al., 2002). The unbalanced 
translocation between chromosomes 1 and 16 
has been associated with poor survival.  It oc-
curs in ~10% of cases and generates der(16)
t(1;16)(q11-21;q11-13) and subsequent gain 
of 1q combined with loss of 16q (douglass 
et al., 1990; hattinger et al., 2002). 
Additionally, increased overall number of 
chromosomal imbalances has been shown to 
correlate with poor prognosis in ESFT (sand-
berg and bridge, 2000; zielenska et al., 
2001). Although mutations affecting tumor 
suppressor gene p53 at 17p13.1 belong to the 
most common genetic alterations identified in 
sporadic human tumors (nigro et al., 1989), 
p53 mutations are rare in ESFT and appear 
only in a small subset of patient samples 
(patino-garcia and sierrasesumaga, 1997; 
tsuchiya et al., 2000; lopez-guerrero et 
al., 2001; huang et al., 2005). However, 
despite the rarity of p53 mutations in ESFT, 
alterations of this gene are associated with 
poor outcome, especially when combined with 
a deletion of the CDKN2A gene (de alava 
et al., 2000; huang et al., 2005). The true 
clinical significance of these secondary genetic 
alterations remains unresolved and controver-
sial, because these alterations are frequently 
described in ESFT but interpretations of their 
clinical significance vary between different 
studies. This again reflects the limited number 
of patients in each individual study.
2 Cancer and inflammation
As early as 1863 Rudolf Virchow observed 
infiltrating leukocytes in tumor tissues and 
made the connection between cancer and 
inflammation. Virchow’s hypothesis was that 
cancers occur frequently at sites of chronic 
irritation, since prolonged inflammation 
fuels cellular proliferation and thereby cancer 
development (schmidt and weber, 2006). 
His early insights were forgotten for many 
decades. However, studies performed in recent 
years have increased our knowledge of the 
role of inflammation in cancer and finally 
established the association between chronic 
inflammation and tumorigenesis (vakkila 
and lotze, 2004). It is now known that 
malignant neoplasms are not composed only 
of genetically aberrant tumor cells but also of 
multiple cell types, e.g., innate and adaptive 
immune cells, fibroblasts, and blood vessel 
and lymphatic vasculature forming cells 
(whiteside, 2008). At the same time as the 
evidence of the important role of inflammation 
in cancer accumulates, the true complexity of 
the connection between tumor development 
and inflammation has really been recognized. 
2.1 Cross-talk between tumor and stroma
Solid tumors are complex tissues that largely 
depend on interaction with the surrounding and 
infiltrating stroma to get the vital physiologic 
support for their malignant progression. This 
dependence is underlined by the fact that 
oxygen can diffuse effectively only 0.2 mm 
distance through living tissues (helmlinger 
et al., 1997). This physical boundary sets the 
growth limits for tumors without functional 
vasculature, since further apart from capillaries, 
tumor growth is in danger of becoming 
necrotic. To overcome this obstacle, tumors 
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recruit endothelial progenitor cells (EPCs) into 
necrotic areas by releasing various cytokines 
and chemokines, e.g., VEGF and CXCL12 
(lewis et al., 1995), which leads EPCs to 
proliferate and differentiate into functioning 
capillaries (jain, 2003). angiogenesis provides 
tumors with adequate access to oxygen and 
nutrients from the blood circulation. Normal 
tissue vasculature is highly organized, but 
neoplasia-associated angiogenesis produces a 
chaotic vascular formation, which frequently 
leaks, and leads to accumulation of fluids in 
the parenchymal spaces within the tumor 
(morikawa et al., 2002; jain, 2003). While 
functional neovasculature within the tumor 
tissue provides infiltrating immune cells an 
easy access to tumor, angiogenesis is also the 
tumor’s gateway to systemic circulation and 
to metastasizing to distant locations of the 
body. Another interesting observation is that 
fibroblasts and myofibroblasts within the tumor 
stroma acquire a phenotype, which resembles 
that of fibroblasts involved in wound healing 
(kalluri and zeisberg, 2006; tlsty and 
coussens, 2006). Some studies have suggested 
that these non-neoplastic myofibroblasts might 
have epigenetic or even genetic alterations in 
their genomes (hu et al., 2005; patocs et 
al., 2007). Characteristically cancer-associated 
fibroblasts (CAFs) express α-smooth-muscle 
actin and they are thought to be important 
promoters of cancer development, angiogenesis, 
invasion, and metastasis (tsukada et al., 
1987; kalluri and zeisberg, 2006). Together 
these observations show how tumorigenesis 
and especially tumor progression are greatly 
dependent on the ability of aberrant tumor 
cells to hijack and exploit the normal cells and 
physiological processes of the host.
2.2 Inflammation as a contributing factor 
for tumorigenesis
Adult cancers, which are often carcinomas, 
result mainly from a multistep process that is 
frequently preceded by a period of prolonged 
chronic inflammation, which can last for 
many years or even several decades (vakkila 
and lotze, 2004). The inflammatory 
microenvironment of these adult tumors 
is characterized by the presence of host 
leukocytes both in the surrounding stroma 
and inside the tumor area (mantovani et 
al., 2008). Inflammation can be caused 
by infectious microbial agents or it can be 
triggered by physical agents or irritants (e.g., 
ultraviolet radiation, tobacco smoke, or asbestos 
fibers). Clear associations between chronic 
inflammatory conditions and cancer have been 
established in, e.g., HPV infection that leads to 
cervitis and cervical cancer (della torre et 
al., 1978), H. pylori induced gastritis that leads 
to gastric cancer (marshall and warren, 
1984), and asbestos-induced asbestosis and 
malignant mesothelioma (wagner et al., 
1960). Additionally, autoimmune disorders, 
such as inflammatory bowel disease that leads 
to colorectal carcinoma, predispose to an 
increased risk of cancer (yang et al., 2009). 
Further, the data indicate that even 15% of the 
total cancer deaths result from the underlying 
infections caused by microbes and that the 
developing countries have the heaviest burden 
of inflammation related cancers (pisani et 
al., 1997). On the other hand, long-term 
usage of non±s teroidal anti-inflammatory 
drugs, e.g., aspirin or other cyclooxygenase-2 
(COX-2) inhibitors, has been shown to reduce 
the risk of colorectal, breast, and gastric cancer 
(gonzalez-perez et al., 2003; wang et al., 
2003; schernhammer et al., 2004). Based 
on these observations we can conclude that 
inflammatory conditions predispose to the 
development of different types of cancer and 
that chronic inflammation can pave the way for 
tumor development, as Virchow suggested. 
Neoplasias with prolonged inflamma-
tion could be described as wounds that never 
heal (dvorak, 1986). Chronic inflammation 
deregulates cellular homeostasis, which can 
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fuel carcinogenesis. Unbalanced tissue homeo-
stasis is characterized by loss of tissue architec-
ture, excessive tissue remodeling, generation of 
pro-inflammatory cytokines and free radicals, 
such as reactive oxygen species (ROS) and 
nitrogen oxide reactive species (RNOS), from 
leukocytes. This process can induce changes 
in the genome and disrupt important cellular 
processes like DNA repair, cell-cycle check-
point regulation, and apoptosis (hussain et 
al., 2003). Tumor-associated macrophages 
(TAMs) are one of the first innate immune 
cell populations to infiltrate the tumor site 
during the early stages of carcinogenesis 
(coffelt et al., 2009). TAMs mature from 
circulating monocytes, which are recruited to 
the tumor site by a chemokine gradient (e.g., 
CC chemokines and CXCL12) released by 
the tumor cells (coffelt et al., 2009). By ac-
cumulating to the necrotic areas of the tumor, 
TAMs have been shown to stimulate neo-
vascularization by expressing pro-angiogenic 
factors like vascular endothelial growth factor 
(VEGF) and interleukin 8 (IL8) (lewis et 
al., 1995). Several clinical studies have shown 
an association between an excessive amount of 
TAMs, increased neovascularization, and poor 
prognosis (leek et al., 1996; takanami et 
al., 1999; onita et al., 2002; kryczek et al., 
2007). Experimental evidence has emerged 
for TAMs’ possible immunosuppressive and 
metastasis-promoting activities (coffelt et 
al., 2009). In addition, malignant neoplasms 
that contain high amounts of other infiltrating 
innate immune cells, like mast cells, are associ-
ated with increased angiogenesis and unfavor-
able prognosis (imada et al., 2000; ribatti 
et al., 2003). Chronic inflammation can drive 
intratumoral accumulation of myeloid-derived 
suppressor cells, which suppress T-cell prolif-
eration and antigen-specific T-cell responses (ga-
brilovich and nagaraj, 2009). Tumor’s ability to 
escape from anti-tumor immunity combined with 
simultaneous exploitation of activated immune 
cells further promotes cancer development.
2.3 Inflammation as a beneficial factor against 
tumorigenesis
Activation of the immune system can also 
put up a fight against the tumor. While 
chronic activation of diverse innate immune 
cells can boost tumorigenesis, full activation 
of adaptive immune system cells can in best 
circumstances result in complete eradication 
of tumor cells. In various cancer types, an 
abundance of infiltrating dendritic cells and 
lymphocytes (T cells and natural killer cells) 
correlates with good prognosis. For example, 
in colorectal carcinoma, gastric carcinoma, 
and adenocarcinoma of lungs, extensive 
natural killer cell infiltration has been shown 
to correlate with favorable clinical outcome 
(coca et al., 1997; ishigami et al., 2000; 
takanami et al., 2001). The beneficial role of 
natural killer cells in tumor microenvironment 
could be explained by their ability to conduct 
crosstalk between the innate and adaptive 
immune systems by interacting with dendritic 
cells and activating them (raulet, 2004). 
Moreover, tumor infiltration of dendritic cells, 
which have a pivotal role in controlling adaptive 
immune responses by presenting antigens to 
T cells, correlates with better outcome, e.g., 
in esophageal carcinoma (furihata et al., 
1992), Hodgkin’s disease (alavaikko et al., 
1994), and tongue carcinoma (goldman 
et al., 1998). Furthermore, the presence 
of tumor infiltrating T cells correlates with 
improved clinical outcome in colorectal cancer 
(naito et al., 1998), esophageal carcinoma 
(schumacher et al., 2001), and ovarian 
carcinoma (zhang et al., 2003). This implies 
that spontaneous activation of anti-tumor 
immunity can be achieved and there is a clear 
association between tumor-host interaction 
and clinical outcome. 
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2.4 Role of inflammation in childhood cancers 
and in ESFTs
Whereas adult cancers are in most 
cases carcinomas, childhood cancers are 
histologically more diverse and they seem to 
arise typically from progenitor or stem cells of 
mesenchymal or ectodermal origin rather than 
from more differentiated epithelial cells. The 
preneoplastic period of childhood neoplasms 
is also much shorter than that of adult cancers. 
Moreover, childhood neoplasms seem to differ 
fundamentally from adult-onset cancers in 
their cell biology and tissue environment, and 
because pediatric cancers develop within a 
short time span, they appear to require fewer 
steps to progress into malignancy (scotting 
et al., 2005). Association between pediatric 
cancers and inflammatory triggers seems to 
be rare, except for some clearly infection-
triggered childhood tumors like Burkitt’s 
lymphoma, which is almost always associated 
with Epstein-Barr virus (EBV) and malaria 
infection as a contributing factor (crawford, 
2001). Moreover, childhood cancers are 
seldom associated with immune cell infiltrates. 
This is supported by observations, which show 
that infiltrates in pediatric neoplasms are 
characterized by macrophages and by a paucity 
of dendritic cells (vakkila et al., 2006). 
Patients with ESFT can have symptoms 
of inflammation in the affected area and some-
times fever. This implies that the inflammatory 
system of ESFT patients can be alerted.  One 
study showed that adenovirus E1A can induce 
EWSR1-FLI1 fusion transcript (sanchez-
prieto et al., 1999), whereas others refuted 
this claim by demonstrating the absence of 
EWSR1 rearrangements in stable or tran-
siently E1A-expressing cell lines of various 
origins and the paucity of E1A sequences in 
genomic DNA of ESFT cell lines and patient 
samples (kovar et al., 2000). Consequently, 
no infectious agent has so far been proven to 
participate in the etiology of ESFT. The role of 
immune system activation in ESFT initiation 
and progression has been studied even to a 
lesser degree. One study suggests that absolute 
lymphocyte count of ≥500 cells/µl on day 15 
after the initiation of chemotherapy corre-
lates with better overall survival in high risk 
ESFT patients and that it is an independent 
prognostic factor for patient outcome (de an-
gulo et al., 2007). This could imply that early 
lymphocyte activation and possibly adaptive 
immune activation have pivotal roles in the 
control of ESFT tumors.
3 CDKN2A aberrations
Tumor suppressor genes, as the name indicates, 
restrain tumor development and growth by 
(1) controlling the progression of cell-cycle, 
(2) repairing mistakes in the genomic DNA, 
and (3) inducing programmed cell death, 
apoptosis, when a cell is damaged beyond 
repair. As normal cells have two copies of each 
allele, tumor suppressor genes are recessive, 
and inactivation of both alleles is required for 
the gene to loose its function in tumor cells. This 
model ± ‘two-hit hypothesis’- was proposed 
already in 1971 by Alfred Knudson based on 
his epidemiological studies of retinoblastoma 
patients (knudson, 1971). His model showed 
that if an individual has a germline mutation 
in one tumor suppressor allele, the probability 
of cancer development, due to a ‘second hit’ 
somatic mutation, is much higher than the 
probability of two independent ‘hits’ in a cell 
of a normal individual (Figure 4). Tumor 
suppressor genes are frequently inactivated in 
cancer cells either by genetic mechanisms (e.g., 
deletions and point mutations) or by epigenetic 
mechanisms (e.g., promoter hypermethylation), 
or by a combination of these mechanisms, 
which suggests that the inactivation of tumor 
suppressor gene contributes to the escape of 
the cell from normal growth control (balmain 
et al., 2003).
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3.1 Biological role of CDKN2A
Tumor suppressor gene CDKN2A (also known 
as p16INK4A/p14ARF or MTS1) was mapped 
to 9p21.3 chromosomal band in April 1994 
almost simultaneously by two research groups 
(kamb et al., 1994; nobori et al., 1994). 
Although the long lasting search for the 
target tumor suppressor gene in the frequently 
deleted chromosomal area of 9p present in 
many cancer patients and cell line samples was 
over,  the role of CDKN2A in normal cellular 
functions and in tumorigenesis was still to be 
determined. The CDKN2A locus encodes 
two tumor suppressor proteins, p16INK4a and 
p14ARF, which are encoded partially by the same 
nucleotide sequences, but read in alternative 
reading frames during transcription under two 
separate promoters (quelle et al., 1995). 
While p16INK4A is encoded by exons 1α, 2, and 
3, the starting exon of p14ARF is 1β, which is 
followed by shared exons 2 and 3 (stone et 
al., 1995) (Figure 5). These two proteins are 
read within a shifted reading frame, which leads 
to two structurally unrelated tumor suppressor 
proteins. The functional role of these proteins 
is to control transition from G1 to S phase 
(p16INK4A) and to act as growth suppressors 
by stabilizing and enhancing p53 function 
(p14ARF). Specifically, p16INK4a inhibits the 
activities of CDK4 and CDK6, which blocks 
phosphorylation of retinoblastoma protein 
(pRB) and subsequent release of E2F (kato et 
al., 1993; serrano et al., 1993). Therefore, 
in the absence of unbound E2F, cell stays in 
G1 arrest. On the other hand, p14ARF interacts 
with MDM2 and thereby inhibits MDM2 
mediated ubiquitylation and degradation of 
p53 (kamijo et al., 1998). In the absence of 
p14ARF, MDM2 promotes rapid degradation of 
p53 through ubiquitylation and proteasomal 
degradation (haupt et al., 1997) leading to 
continuation of cell cycle to the S phase (for 
detailed information of p16INK4A and p14ARF 
functions, see Figure 5). This demonstrates 
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Figure 4. Knudson’s “Two-hit hypothesis”. 
Genetic aberrations in tumor suppressor genes are recessive 
in nature and therefore both copies of tumor suppressor 
genes need to be silenced. Germline mutations in tumor 
suppressor genes are most commonly point mutations or 
microdeletions, since alterations of larger segments in the 
genome can pose more profound negative effects on cell 
function. Somatic mutations, on the other hand, can vary 
from losses of whole chromosome arms to small point 
mutations. 
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that proper cell-cycle control requires both of 
these proteins.
3.2 Role of CDKN2A in cancer and in ESFT
High frequencies of CDKN2A deletions and 
mutations are found in a wide range of tumor 
cell lines (kamb et al., 1994; nobori et al., 
1994) and in primary human tumors (cairns 
et al., 1995). Inactivation of both CDKN2A 
alleles can confer an abnormal cellular self-
renewal, which is the hallmark of cancer 
development. Inactivation of CDKN2A can 
be achieved either by homozygous deletion, 
point mutations, promoter methylation, 
or by combination of these mechanisms. 
Homozygous deletion of CDKN2A seems 
to be the predominant mechanism of 
inactivation, since small lesions like point and 
frame shift mutations and methylation on 
the promoter area are detected at much lower 
frequencies (park et al., 1999; tsuchiya et 
al., 2000; ortega et al., 2002). In addition 
to sporadic alterations, various CDKN2A 
germline mutations with a specific target on 
exon 1α have been detected in individuals 
with familial melanoma (hussussian et al., 
1994). This underlines the important role of 
CDKN2A in tumorigenesis and the fact that 
it contributes to familial cancers when the 
remaining wild type allele is lost by somatic 
genetic alteration in agreement with the 
Knudson’s two-hit proposal. Silencing of 
CDKN2A has been associated with adverse 
outcome in several cancer types, i.e., ALL 
(kees et al., 1997; calero moreno et al., 
2002), malignant mesothelioma (dacic et 
al., 2008), and hepatocellular carcinoma (ko 
et al., 2008). In ESFT patient samples, loss 
of CDKN2A is present in 10-30% of patients 
(kovar et al., 1997; tsuchiya et al., 2000; 
wei et al., 2000; lopez-guerrero et al., 
2001; brownhill et al., 2007), whereas in 
ESFT cell line samples the frequency rate of 
CDKN2A alterations can reach 50% (kovar et 
al., 1997; obana et al., 2003). This indicates 
the selection pressure for CDKN2A alterations 
to allow and increase in vitro cell growth. 
Moreover, homozygous deletion of CDKN2A 
has been shown to be a poor prognostic sign 
for Ewing sarcoma patients (tsuchiya et al., 
2000; wei et al., 2000; huang et al., 2005; 
honoki et al., 2007).
3.3 Detection of CDKN2A alterations in 
clinical diagnostics
The fact that CDKN2A has a pivotal role 
in inhibiting tumorigenesis and that it is a 
prognostically significant marker in several 
cancers makes it also a useful biomarker in 
clinical diagnostics. More than 1400 different 
germline and somatic mutations are known 
to occur in the CDKN2A locus (murphy et 
al., 2004), which makes it a challenging target 
for clinical applications. CDKN2A mutations 
Figure 5. CDKN2A gene structure and function. Cell 
cycle brakes are marked with red and accelerators are 
marked with green. Figure 5 is modified from sekulic et 
al. 2008.
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can be detected using, for example, PCR 
and sequencing (harland et al., 2008). 
Aberrations in CDKN2A copy number can 
be detected using various techniques, e.g., 
Southern blotting, FISH, quantitative PCR, 
or array comparative genomic hybridization 
(aCGH). In clinical diagnostics, CDKN2A 
copy number aberrations are most commonly 
detected using commercial FISH probes of 
150-200 kb in size, because the method is 
rapid and sensitive, and the results are easy to 
interpret (for detailed information on FISH 
technique, see Figure 6). Detection of CDKN2A 
aberrations by FISH can be performed on 
both metaphase and interphase cells or 
on paraffin-embedded samples, which offers 
it a wide range of possible applications. 
Quantitative PCR (qPCR) analysis is another 
cost-effective technique to detect CDKN2A 
alterations in clinical diagnostics, although 
contamination with normal cells or clonal 
heterogeneity can hamper data interpretation. 
This can lead to false negative results, which 
decreases the reliability and sensitivity 
of qPCR in the detection of CDKN2A 
aberrations. Therefore FISH still seems to be 
the most reliable method to detect homozygous 
CDKN2A deletions, although the analysis also 
has its limitations, especially in detecting small 
(<100kb) deletions. 
4 Molecular profiling of cancer by 
microarrays
Progress in the field of human genetics has 
been dramatic ever since James Watson and 
Francis Crick discovered the double helix 
structure of DNA in 1953 (watson and 
crick, 1953). Chromosomes in human cells 
were first seen by Walther Fleming already in 
1882. However, the 46 chromosomes in the 
human nucleus were not detected until 1956 
(tjio and levan, 1956). In 1968, fundamental 
advances in cytogenetics followed from 
the development of chromosomal banding 
Figure 6. Fluorescence in situ hybridization (FISH) 
technique in CDKN2A deletion detection. 
(A) FISH is a molecular cytogenetic technique, which can 
be used to detect the presence or absence of a specific DNA 
sequence in a dividing metaphase nucleus or in a non-dividing 
uncultured interphase cell of interest. FISH is based on the 
ability of unique single-stranded DNA probe to anneal with 
its complementary target sequence with high specificity. In 
order to perform FISH analysis, probes are first prepared 
by amplifying the genomic sequence of interest and then by 
labeling it with fluorescent dyes, e.g., Cy3 for a green signal 
or Cy5 for a red signal, either by using nick-translation or 
random-primed labeling. Then these probes are denatured to 
generate single-stranded form and hybridized to the sample 
of interest. The result can be interpreted using fluorescence 
microscope. (B) Schematic examples of FISH analysis results 
from locus-specific FISH on CDKN2A aberration. Red 
signal is detected when a locus-specific FISH probe binds to 
an intact CDKN2A locus and green signal is detected when 
the control probe binds to a centromeric repeat sequence. 
Interpretation of these signals reveals the lack of changes in 
the copy number of CDKN2A (normal), whether CDKN2A 
is gained or heterozygously or homozygously deleted. 
Figure 6A is modified and reprinted from www.genome.
gov/glossary.cfm and used with permission from National 
Human Genome Research Institute.
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technique that used metaphase nuclei stained 
with alkylating agents, such as quinacrine, to 
produce identifiable patterns of light and dark 
bands on each chromosome (caspersson 
et al., 1968). However, preparation of high 
quality metaphase spreads is often challenging, 
especially in solid tumors. In the 1980s, the 
FISH technique using fluorescent dyes with 
in situ hybridization was introduced (van 
prooijen-knegt et al., 1982) and it has paved 
the path for the development of microarray 
techniques for detection of changes e.g. in 
gene copy number and expression.
4.1 Gene copy number profiling by array CGH
Comparative genomic hybridization (CGH) is 
a molecular cytogenetic technique that detects 
and maps alterations in copy number of 
DNA sequence (kallioniemi et al., 1992). 
Although conventional CGH revolutionized 
the field of cytogenetics in the 90s when 
dividing cells and metaphase spreads were no 
longer required, it still had limitations. The 
main drawback of conventional CGH is its 
low resolution, since aberrations smaller than 
5-10 Mb cannot be detected (forozan et al., 
1997). To overcome this limitation, metaphase 
chromosomes were replaced by a large number 
of mapped clones of DNA spotted onto a 
standard glass slide for more accurate detection 
of chromosomal imbalances (solinas-toldo 
et al., 1997; pinkel et al., 1998). 
In array CGH, DNA from the test sam-
ple and normal reference sample are extracted, 
digested, and thereafter labeled with different 
fluorochromes, most commonly by Cy5 (red) 
for test sample and Cy3 (green) for reference 
(Figure 7). The labeled samples are then com-
bined in equal amounts and hybridized onto 
the array slide, which contains probes for the 
specific target sequences. During hybridiza-
tion, the combined samples compete for the 
complementary hybridization sites and if a 
Figure 7. Overview of microarray technology, which can be applied to gene copy number and expression studies.
Figure 7 has been reprinted and modified from www.genome.gov/glossary.cfm with permission from National Human 
Genome Research Institute.
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certain genomic sequence is gained in the 
test sample, the corresponding probes on the 
array slide become predominantly red. Vice 
versa, if a certain genomic sequence is lost in 
the test sample, the complementary probes on 
the slide become green. Then the array slide 
is washed and the images of both fluorescent 
dyes are captured by scanning. The ratios of 
fluorescence intensity are calculated to extract 
information about gene copy number changes 
on different chromosomal locations. The end 
result is a global overview of the chromosomal 
imbalances in the entire test sample genome. 
The resolution of the data is only limited 
by probe lengths and the distance between 
the probes (Table 2). The use of large-insert 
clones like bacterial artificial clones 
(BACs) (solinas-toldo et al., 1997) has 
the advantage of producing intense and robust 
signals, albeit the resolution is limited to ~1 
Mb. Complementary DNA (cDNA) probes, 
usually 1-2 kb in size, have also been used 
in array CGH applications (pollack et al., 
1999). Their main advantage is higher resolu-
tion and the possibility to carry out expression 
analysis using the same platform. The highest 
resolution in array applications can be achieved 
using spotted oligonucleotide probes of 60-70 
nucleotides in size (brennan et al., 2004; 
carvalho et al., 2004). Single nucleotide 
polymorphism (SNP) microarrays, which use 
in situ hybridized 25-mer oligonucleotides, 
were initially designed for genotyping purpos-
es, but are now also adopted for copy number 
analysis (bignell et al., 2004; zhao et al., 
2005). The advantage of SNP array is that it 
enables the study of copy number neutral loss 
of heterozygosity (LOH) due to unipa-
rental disomy (UPD) (cowell and lo, 
2009; tuna et al., 2009). Agilent arrays use 
spotted 60-mer oligonucleotides. This platform 
has been proven to offer higher sensitivity and 
specificity as compared with Affymetrix SNP 
microarray (using in situ hybridized oligonu-
cleotides), which, on the other hand, provides 
better detection of copy number aberrations in 
gene-poor areas (greshock et al., 2007). The 
amount of oligonucleotide probes on the ar-
ray slides is almost infinite, depending merely 
on the technology available and, at the time 
of writing, arrays with more than one million 
probes on each slide can be applied to research 
or diagnostic purposes. It should also be noted 
that small and large scale copy number varia-
tions (CNVs) are widespread and common 
in normal individuals, and thereby present an 
important source of genetic variation in the 
human genome (sebat et al., 2004; tuzun 
et al., 2005; redon et al., 2006). CNVs 
can have an impact on disease susceptibility 
and they are also likely to play a role in cancer 
etiology (shlien and malkin, 2009; zhang 
et al., 2009).
The main deficiency of array CGH is 
that is not able to detect copy number balanced 
chromosomal aberrations, e.g., translocations 
Method Probe size Resolution Genome-wide coverage 
Karyotyping Not applicable Chromosomal bands (~10 Mb) Complete
Spectral karyotyping Not applicable > 1 Mb Complete
Conventional CGH Metaphase chromosomes Chromosomal bands (~10 Mb) Complete
Fiber FISH 1-500 kb 1-500 kb Probe specific
Interphase FISH > 50 kb > 50 kb Probe specific
Metaphase FISH > 50 kb > 1 Mb Probe specific
BAC array CGH 100-200 kb > 1 Mb Complete
cDNA array CGH 0.5-2 kb > 100 kb Genes only
Oligonucleotide array CGH 45-60 nt > 20 kb Complete
SNP array CGH ~25 nt > 50 kb Complete
Table 2. Comparison of different cytogenetic and molecular genetic techniques
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and inversions. Obviously more subtle changes 
in the genome, like point mutations, can not 
be detected either. Moreover, array CGH fails 
to detect genome-wide copy number changes, 
such as ploidy, which are present in some tu-
mor samples. For these aberrations, other cy-
togenetic techniques like multicolor FISH or 
spectral karyotyping (SKY) have to be applied. 
Overall, it should be noted that combining of 
different methods improves the reliability of 
genetic analysis, which is especially crucial in 
diagnostic applications. But the array CGH 
technique provides several clear advantages 
as compared with other techniques: (1) no 
prior knowledge about the genetic imbalance 
of interest is needed, (2) high-resolution data 
on whole genome scale in a single experiment 
is obtained, (3) the method is highly sensi-
tive and specific, and (4) the protocol can 
be partially automated for high-throughput 
applications. Due to these advantages, array 
CGH techniques are being established not 
only for diverse goals in basic research but also 
for diagnostic applications (shinawi and ch-
eung, 2008) (see also Table 3 for more specific 
information). 
4.2 Gene expression profiling by array 
technologies
After the human sequence project was 
completed in 2001 (lander et al., 2001; 
venter et al., 2001), the focus was 
1. Genome-wide gene expression and copy number screening
2. High-resolution analysis of the regions of interest in the cancer genome
3. Tumor classification and reorganization of tumor categories
4. Identification of novel diagnostic or prognostic markers or fingerprints
5. Identification of novel therapeutic targets 
6. Characterization of activated or inactivated pathways in tumor 
7. Complex modeling of cancer dynamics
8. Attempts to personalize treatment based on the genetic properties of a tumor
Table 3. Applications of expression and copy number microarray technologies in basic cancer research and in diagnostic 
applications
increasingly diverted towards understanding 
of functional genomics, which aims to decode 
dynamic aspects of the genome, such as gene 
expression and translation. Gene expression 
levels in cells of interest can be measured 
by several methods, e.g., Northern blotting, 
different PCR applications (including 
quantitative real time PCR), and in situ 
hybridization. However, these techniques 
limit the scope of study to the behavior of 
one single gene at a time. Propitiously, the 
improvements in molecular genetic tools, 
especially expression microarrays, have enabled 
scientists to investigate global gene expression 
patterns to better understand diseases like 
cancer. In this context, expression microarrays 
can help us refine subclassification of cancer 
entities, characterize their biology in more 
detail, and, most importantly, provide novel 
diagnostic markers and therapeutic targets 
based on expression profiles of individual 
samples (Table 3). 
DNA microarrays for gene expression 
studies are prepared either (1) by printing 
pre-produced DNA probes to a solid surface 
(spotted cDNA and oligonucleotide arrays) 
(hughes et al., 2001) or (2) by chemically 
synthesizing DNA probes on a solid surface 
using photolithography (pease et al., 1994). 
Gene expression microarray analysis can be 
performed as a one-color experiment, when 
the sample of interest is labeled with a single 
color and hybridized to the microarray without 
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a reference sample, which is hybridized in an-
other one-color experiment (e.g., Affymetrix 
in situ hybridized oligonucleotide platforms). 
In a two-color experiment, the sample of 
interest and the reference sample are labeled 
differentially with compatible fluorochromes 
and they hybridize competitively to the array 
probes (see Figure 7). The benefit in using this 
approach is that a single two-color experi-
ment leaves less room for variation than two 
independent one-color experiments, because 
the hybridization conditions are identical. 
However, the primary causes of variation 
in the results are the biological samples and 
human factors, rather than technical diversity 
(irizarry et al., 2005). In both approaches 
the expression levels of genes are monitored 
simultaneously on genome-wide scale. 
4.3. Microarray data analysis
Laboratory techniques to produce microarray 
data have advanced substantially and, most 
significantly, a level of sufficient quality has 
been achieved in skilful laboratories. In this 
regard, the technology is no longer a limiting 
factor for microarray analysis. However, there 
is still much room for improvement in data 
analysis and interpretation, which are lagging 
behind and causing bottlenecks in microarray 
analysis.
Microarray data analysis begins by 
image analysis to locate and quantify the 
 intensities of probe spots, which reflect the 
copy number or expression of genes. The 
 analysis  continues with subsequent filtering of 
the image data to select a subset of the available 
probe measurements for exclusion or inclusion 
in further analysis based on the quality of the 
measurement. Basic image analysis and data 
filtering function well, but lacking standard-
ized protocols, scientists are performing the 
procedures according to their own experience. 
Consequently, this phase can produce discrep-
ant results and cause thereby difficulties in 
data comparison between different laborato-
ries and different experiments. Next, data nor-
malization is carried out to adjust individual 
hybridizations and to remove variation caused 
by factors other than intrinsic biological dif-
ferences in the samples of  interest. The varia-
tion that needs to be excluded can result from 
differences in, e.g., dye labeling, hybridization, 
batch effect in microarray slide printing, or 
experimental conditions. Again, no standards 
have been specified for normalization and 
procedures are therefore chosen in accordance 
with their applicability to each individual 
experiment. A multitude of different normal-
ization algorithms is available, as reviewed by 
Quackenbush (quackenbush, 2002), but the 
most widely used is locally weighted scat-
ter plot smoothing (Lowess) (cleveland, 
1979). The normalization method must be 
selected with caution, because advanced 
normal ization methods can lead to overfit-
ting, which can  effectively remove biologically 
relevant  information and introduce bias to the 
analysis. Various algorithmic approaches have 
been developed for identifying copy number 
 alterations, their breakpoints, and differences 
in genome-wide gene expression, both as an 
open source, e.g., Bioconductor (gentleman 
et al., 2004) and CGH-Explorer (lingjaerde 
et al., 2005), and as commercially available 
packages (e.g., Agilent Feature Extraction and 
Agilent CGH Analytics).  Moreover, attempts 
to improve data comparison have been made, 
and as a result, the Minimum Information 
About a Microarray Experiment (MIAME) 
guidelines for microarray data annotation and 
reporting have been adopted by the scientific 
community (brazma et al., 2001). 
34
35
Novel target genes and biomarkers in ESFTs are needed because of their aggressive behavior and 
subsequent poor survival. Because no specific ESFT treatment is currently available and mostly 
children and young adults are affected, it is vitally important to find novel target molecules and 
therapeutic strategies. Hence, the treatment of ESFT fundamentally requires more profound 
knowledge of the molecular properties of these tumors. Secondly, as genetic aberrations of 
CDKN2A are associated with a more aggressive course of the disease, accurate characterization of 
CDKN2A alterations provides crucial data for more reliable criteria of patient classification into 
groups with favorable or poor prognosis. Therefore, the specific aims of this study were:
To identify genes involved in ESFT tumor progression using array CGH and expres-1. 
sion analysis, and to identify the chromosomal rearrangements that can be used in 
differential diagnostics of ESFT patients (I),
To perform bioinformatic analysis of gene expression profiles in ESFT in order to 2. 
characterize the inflammatory signals produced by these tumors and to reveal prognos-
tically significant target molecules for potential drug therapy (II),
To screen 9p21.3 and 3. CDKN2A deletion sizes and frequencies in ESFT in order to 
provide new information for grouping of high-risk patients and also to screen these 
 aberrations in another cancer of children and adolescents, acute lymphoplastic leu-
kemia (ALL), in order to provide data for developing a novel diagnostic method for 
reliable detection of CDKN2A deletions (III, IV).
Aims of This Study
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an overview of materials and methods 
is presented in the following sections. More 
detailed technical descriptions can be found in 
the corresponding publications marked with 
Roman numerals.
5 Patient and cell line material and 
gene lists
5.1 ESFT patient samples (I, II, III)
Fresh frozen samples (stored at -70°C to 
preserve RNA and DNA from degradation) 
of ESFT patients were collected prospectively 
from the archives of the Laboratory of 
Oncologic Research, Istituti Ortopedici 
Rizzoli (IOR), Bologna, Italy. All the tissue 
samples were reviewed on histological sections 
by a pathologist. Patients were treated within 
controlled prospective trials as reported in 
detail in previous papers (rosito et al., 1999; 
bacci et al., 2007). Detailed data about 
clinical parameters are available in publications 
I, II, and III. 
5.2 ESFT cell line samples and cell 
culturing (II, III)
For gene expression analysis in study II and 
for copy number analysis in study III, the 
following 11 ESFT cell line samples were 
obtained from Laboratory of Oncologic 
Research, Istituti Ortopedici Rizzoli, Bologna, 
Italy: LAP35, 6647, TC71, RDES, SKES-1, 
SKNMC, IOR/CLB, IOR/RCH, IOR/CAR, 
IOR/BRZ, and IOR/NGR. These ESFT cell 
lines have been described in detail in a previous 
publication (manara et al., 2002). For FISH 
analysis (study III), a fresh IOR/RCH cell line 
was obtained from Rizzoli Institute (Bologna, 
Italy) and it was cultured at humidified +37ºC, 
5% CO2 atmosphere in Iscove’s Modified 
Dulbecco’s Medium (IMDM) with 10% heat 
inactivated Fetal Bovine Serum (FBS), 100 
µg/ml streptomycin, and 20 U/ml penicillin 
(Gibco). The cells were subcultured every 
3-4 days by diluting them in fresh culture 
medium.
5.3 ALL patient samples (IV)
For study IV, bone marrow samples of 54 
ALL patients aged between 10 and 25 years 
Materials
& Methods
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were collected for copy number analysis. The 
clinical data of these patients were extracted 
from the Nordic NOPHO ALL and Finnish 
Leukemia Group ALL databases. All patients 
were treated according to the Nordic (pediatric 
patients 10±16 years, n=33) and Finnish 
Leukemia Group protocols (adult patients 
17±25 years, n=21). Detailed data about the 
clinical parameters are available in publication 
IV.
5.4 Healthy control samples for genetic studies 
(I, II, III, IV)
For studies I, III, and IV, male and female 
reference genomic DNAs for the copy number 
analysis were pooled from blood samples (4 
individuals) obtained from the Finnish Red 
Cross Blood Transfusion Service (Helsinki, 
Finland). For gene expression studies of 
HDGF and CDKN2A (studies I and III), 
normal muscle samples were pooled from three 
individuals and CD34+ cells were derived from 
human bone marrow. For control samples in 
study II, we utilized previously published 
Human Genome U133 Plus 2.0 expression 
data on normal skeletal muscle tissue samples 
(n=18). These data were extracted from publicly 
available Gene Expression Omnibus database 
(www.ncbi.nlm.nih.gov/geo/) (barrett et 
al., 2007) with GEO accession numbers 
GSE6798 and GSE3526.
5.5 Annotated gene lists and gene expression 
signatures (II)
A list including 238 genes putatively related 
to inflammation was constructed by literature 
review and the list was subdivided to six groups, 
each consisting of genes related to a particular 
type of inflammation response. Additionally, a 
macrophage related gene expression signature 
was derived by filtering SymAtlas data (su et 
al., 2002), which contains Affymetrix U133 
gene expression data from 122 normal cells 
and 90 cancer cell lines. Macrophage specific 
gene signature (n=299) was extracted by 
filtering SymAtlas data of 18 samples from the 
immune system specific cell types, of which 
two were CD14 positive cells, according to the 
present/absent flags of MAS5 preprocessed 
Affymetrix data. 
6 Analysis methods
6.1 Nucleic acid extraction (I, II, III, IV)
For studies I and III, genomic DNA was 
extracted from fresh frozen ESFT patient 
samples (n=31) and fresh ESFT cell lines 
(n=11) using the standard phenol±c hloroform 
method. Prior to extraction, the proportion of 
tumor cells in patient samples was verified to 
exceed 75% in all samples by using hematoxylin 
and eosin-stained sections. Tissue necrosis was 
evaluated on the whole tumor mass. In cases 
with high percentages of necrosis, nucleic 
acids were isolated from the tissue samples, in 
which viable cells were still present.
For studies I, II, and III, RNA from 
ESFT patient samples (n=44) and cell lines 
(n=11) was isolated using a TRIzol extraction 
kit (Invitrogen Ltd., Paisley, UK) according to 
the manufacturer’s recommendations. 
For study IV, genomic DNA from 
ALL patients (n=54) was extracted either 
from frozen bone marrow, bone marrow cell 
nuclei in fixative (acetic acid±met hanol, 1:3), 
or bone marrow cell pellets stored at -70°C. 
For frozen samples, a standard non-enzymatic 
phenol±c hloroform method was used. For 
fixatives and for frozen cell pellets, Puregene 
DNA Purification Kit (Gentra Systems, 
Minneapolis, MN, USA) was used.
Concentrations of extracted DNA 
and RNA samples were measured using 
either GeneQuant pro spectrophotometer 
(Amersham Pharmacia, Cambridge, UK), or 
NanoDrop spectrophotometer (NanoDrop 
Technologies Inc., Wilmington, DE, USA). 
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The quality of DNA was checked using agarose 
gel electrophoresis and the quality of RNA 
was assessed using Agilent’s 2100 Bioanalyzer 
(Agilent, Palo Alto, CA, USA).
6.2. Microarray experiments and data analysis
6.2.1 Gene copy number analysis with Agilent 
microarrays (I, III, IV)
Digestion, labeling, hybridization, and 
data analysis of genomic DNA were 
performed according to the manufacturer’s 
recommendations using Agilent protocol 
version 2.0 for 44K arrays (studies I, III, and 
IV) and version 4.0 for 244K arrays (study III). 
The sample and reference genomic DNAs, 7 
µg each, were digested and, depending on the 
available material, 0.9±1.5 µg of fragmented 
DNA was labeled for 44K arrays by random 
priming using the BioPrime array labeling kit 
(Invitrogen, Carlsbad, CA, USA) with Cy5-
dUTP and Cy3-dUTP dyes (PerkinElmer, 
Wellesley, MA, USA), and for 244K arrays 
using Genomic DNA Labeling Kit (Agilent). 
Labeled samples were purified using Microcon 
YM-30 filters (Millipore, Bedford, MA, USA), 
combined and hybridized to Human Genome 
CGH 44B oligomicroarray slides or 244A 
oligomicroarray slides (Agilent Technologies 
Santa Clara, CA, USA) against their gender-
matched reference DNAs. After 40 h 
hybridization at 65°C, 10 rpm, the slides were 
washed and scanned using Agilent’s microarray 
scanner G2565BA (Agilent). The images 
were analyzed and the data were extracted 
using Feature Extraction Software (Agilent) 
version 8.1 (44K arrays) and 9.1 (244K arrays) 
including dye normalization (Linear Lowess) 
and background subtraction. For data analysis, 
Agilent’s CGH Analytics software versions 
3.2 (study III), 3.3 (study III), and 3.4 (studies 
I and IV) were used. The chromosomal 
aberrations were scored, and the starting 
and ending points of the aberrations were 
confirmed by either the ADM-1 algorithm 
with threshold at 5.0 for studies I, III, and IV 
or by the Z-score algorithm with threshold 
at 2.5 using 1 Mb (for 44K analysis) or 0.5 
Mb window (for 244K analysis). Calibration 
hybridizations were performed using male vs. 
male and female vs. male reference samples to 
reduce internal variation in data analysis and 
to provide controls for gain and loss levels. 
Regarding 9p21.3 analysis (for studies III 
and IV), our results were compared with the 
entries in the Database of Genomic Variants 
(projects.tcag.ca/variation/) to rule out the 
possibility of copy number polymorphism in 
the CDKN2A locus.
6.2.2 Gene expression analysis with Affymetrix 
microarrays (I, II)
RNA samples from ESFT patients and cell 
lines were hybridized to Affymetrix Human 
Genome U133 Plus 2.0 oligonucleotide 
microarrays (Affymetrix, Santa Clara, CA, 
USA) according to the manufacturer’s 
GeneChip® One-Cycle Target Labeling 
protocol. Briefly, 5 µg of total RNA was 
reverse transcribed to cDNA using One-Cycle 
cDNA Synthesis Kit (Affymetrix). Biotin-
labeling of antisense cRNA was carried out 
using IVT Labeling Kit (Affymetrix). The 
labeled and fragmented cRNA was then 
hybridized for 16 h at 45°C in a hybridization 
oven 640 (60 rpm). Washing and staining of 
the arrays with streptavidin-phycoerythin 
(SAPE) was completed in a Fluidics Station 
450 (Affymetrix). Washed arrays were scanned 
on confocal laser GeneChip Scanner 3000 
and images were analyzed using GeneChip 
Operating Software (GCOS; Affymetrix, 
Sacramento, CA, USA). The original 
microarray data of these samples are available 
at Gene Expression Omnibus (barrett et 
al., 2007) with accession number GSE17679.
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6.3 Validation of the microarray results
6.3.1 Quantitative real time PCR analysis 
(I, III)
Both HDGF gene expression (study I) and 
CDKN2A gene expression (study III) analyses 
by qPCR were performed using pre-designed 
TaqMan probe and primer sets: HDGF with 
Assay ID Hs00610314-m1 and CDKN2A 
with Assay ID Hs00233365_ml (Applied 
Biosystems, Foster City, CA, USA). Probe 
and primer sets were factory-loaded into the 
384 wells of TaqMan Low Density Arrays 
with two replicates. All PCRs were carried 
out using ABI PRISM 7900 Sequence 
Detection System (Applied Biosystems) as 
recommended by the supplier. Thermal cycling 
conditions for HDGF were 50°C for 2 min, 
95°C for 10 min, 95°C for 15 s, and 60°C for 
1 min, and for CDKN2A the conditions were 
50°C for 2 min, 94°C for 10 min, 97° C for 
30 s, and 59.7°C for 1 min. Gene expression 
values were calculated based on the ∆∆ Ct 
method (livak and schmittgen, 2001). 
In study I, RNA from CD34+ cells derived 
from human bone marrow and pooled muscle 
normal tissues derived from three individuals 
were the designated calibrators for the analysis 
of all other samples and, in study III, a pool 
of normal muscle tissue was the designated 
calibrator for the analysis of all other samples. 
Further, expression values were normalized 
with respect to a housekeeping gene (GAPDH) 
and to normal tissues samples.
6.3.2 Immunohistochemical analysis (II)
In study II, to validate C5a and C5aR expression 
findings, immunohistochemical analysis was 
performed on an independent tumor tissue 
microarray (TMA) of ESFT patient samples. 
Avidin-biotin-peroxidase procedure was 
used for immunostaining. TMA slides were 
stained for C5a with anti-C5 goat antiserum 
(Quidel, San Diego, CA, USA) using dilution 
1:100 and for C5aR with anti-C5aR1 rabbit 
polyclonal antibody (Abcam, Cambridge, 
UK) using dilution 1:200. For C5a staining, 
heart was used as the positive control and for 
C5aR, kidney was used as the positive control. 
The patients were scored microscopically as 
negative or positive based on immunoreactivity 
of the respective antibody on tumor cells. 
6.3.3 Fluorescence in situ hybridization 
analysis (III)
Chromosome preparations were performed 
according to standard procedures. Briefly, 
Colcemid (KaryoMAX, Gibco, Invitrogen 
Coproration) was added to concentration of 
0.1µg/ml in the cell culture suspension when 
cells were in their exponential growth phase. 
After 16h Colcemid incubation, cells were 
treated with hypotonic solution (56 mmol/l 
KCL) followed by three fixations in fresh 
3:1 methanol/acetic acid solution. Then, 
nuclear suspension was dropped on glass 
slides followed by drying. FISH analysis was 
performed using a commercial p16(INK4a) 
gene probe (LSI p16/CEP9 Dual Color probe, 
Vysis, Abbot Laboratories, IL, USA) according 
to the manufacturer’s instructions. The length 
of 9p21 LSI p16 spectrum Orange probe 
(~190 kb) covers genomic markers D9S1749, 
D9S1747, D9S1748, and D9S1752. CEP9 
spectrum green probe covers chromosome 
bands 9p11-q11. Homozygous or heterozygous 
deletion of the CDKN2A gene is represented 
by loss of one or two orange CDKN2A 
signal(s), respectively, while retaining two 
green centromeric signals from chromosome 
9. Gain in the CDKN2A gene is represented 
by gain of the orange CDKN2A signal. At least 
20 nuclei per sample were studied to confirm 
the results and the experiment was conducted 
in three replicates.
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6.4 Computational analysis (I and II)
RNA and DNA level data were integrated by 
custom-made bioinformatic analysis in study I. 
In the joint analysis, each Affymetrix probe 
set was paired with the closest Agilent probe, 
measured as the distance between the mean 
points of the sequences. The Affymetrix probe 
sets that had no Agilent probes within 375 kb 
were ignored. Correlation between expression 
and gene copy number of different patients was 
measured separately for each gene (identified 
based on the Affymetrix probe set). Genes 
with high positive or negative correlation were 
chosen for further examination.
In study II, differential inflammatory 
and macrophage gene expression was measured 
for each gene by a combination of two-sided t-
test and fold change comparison in two sepa-
rate tests: (1) between the patient and cell line 
samples and (2) between the patient samples 
and muscle tissues. For both experiments, the 
corresponding gene expression measurements 
were preprocessed using the Robust Multi-
Array Average (RMA) (irizarry et al., 
2003), and the p-values of the t-test were cor-
rected for multiple testing using the q-value 
procedure (storey and tibshirani, 2003). 
In order to be considered as differentially 
expressed, the following thresholds were used: 
q-value <0.01, indicating false discovery rate 
(FDR) of 1%, and fold change >1.6 (Ewing 
patient samples vs. cell lines) or >2.15 (Ewing 
patient samples vs. muscle tissue). The thresh-
olds for the fold change were based on the 
expression levels of 14 housekeeping genes. 
6.5 Statistical analysis (I, II, IV)
Statistical analysis of patient survival and 
evaluation of the prognostic value of the most 
interesting genetic aberrations were performed 
using the SPSS software (SPSS Inc., Chicago, 
IL, USA), versions 15.0 and 16.0. Survival 
calculations were based on Kaplan-Meier 
estimates and differences in significance were 
tested using a log-rank test. If not otherwise 
stated, p≤0.05 was considered statistically 
significant. Event-free survival (EFS) was 
defined as the time from diagnosis to the first 
event (relapse, death, or second malignancy) 
and overall survival (OS) as the time from 
diagnosis to death. In order to compare the 
clinical characteristics, the Mann± Whitney 
U-test was used for continuous and the Chi-
square test for categorized variables.
7 Ethical permissions
The study protocols were approved and 
authorized by the appropriate ethical review 
boards of the respective institutes: for studies 
I-III by the Ethics Review Committee of the 
Hospital District of Helsinki and Uusimaa 
(decision numbers 329 HUS/E0/05 and 
328 HUS/E0/05), and for study IV by the 
appropriate Institutional Review Boards 
and the National Authority for Medicolegal 
Affairs. In order to ensure the anonymity of 
the patients, a generic sample code was given 
to each specimen and all personal data were 
eliminated when subjected to research.
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8 DNA copy number changes and their 
correlation with gene expression in ESFT 
patients (Study I)
The prognosis of ESFT patients suffers from 
lack of adequate predictive markers for proper 
classification at the time of diagnosis. Novel 
biomarkers are therefore urgently needed for 
better ESFT patient management. In this study, 
array CGH analysis was conducted to identify 
clinically relevant copy number changes in 
ESFT patients and to determine how the 
findings correlate with gene expression. This 
strategy was based on the fact that integration 
of data from both genomic and transcriptional 
levels provides more accurate insights into 
the underlying events in tumor cells than do 
genetics or histology alone.
Secondary chromosomal changes, 
mainly chromosomal gains, were identified in 
87% of the cases analyzed (Figure 2 in I). The 
most common copy number changes detected 
in ESFT patient samples were gains at 1q, 
2, 8, and 12, and losses at 9p and 16q. Our 
data showed that a small number of secondary 
chromosomal changes are associated with 
better prognosis in primary ESFT. Primary 
ESFT patients with ≤3 copy number changes 
have significantly better event-free survival 
(p=0.05) and overall survival (p=0.03) than 
 patients with a higher number of chromosomal 
aberrations (Figure 1 in I). This is in line with 
previous observations that the numerous chro-
mosomal aberrations in ESFT associate with 
poor clinical survival (sandberg and bridge, 
2000; zielenska et al., 2001). In addition, a 
recent study of 88 ESFT patients showed that 
patients with complex karyotypes or whose 
chromosome number was >50 are more likely 
to have a particularly poor outcome (roberts 
et al., 2008). Moreover, the six-year follow-
up of our patient cohort showed that only 27% 
(3 of 11) of patients with less than three copy 
number changes were diagnosed with metas-
tases, whereas 80% of the patients with more 
than three copy number changes developed 
metastases (p=0.03). This confirms that the 
number of chromosomal aberrations can be 
prognostically relevant, even when the number 
of patients in our study was small.  
Previous studies in our group have 
shown that apparently balanced translocations 
can be associated with copy number changes 
like deletions and amplifications as secondary 
genetic alterations at the breakpoint regions 
of translocations (tyybäkinoja et al., 2007). 
Results &
Discussion
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In the present study, the translocation type 
(EWSR1-FLI or EWSR1-ERG) of ESFT 
patients was determined using RT-PCR at 
the time of diagnosis (Table 1 in I). Further 
study using array CGH approach showed that 
duplication of the derivative chromosome, 
der(22)t(11;22) that leads to gain of ESWR1-
FLI1 fusion gene, was present in three cases 
(D153, D248, and D254), which comprise 
10% of our ESFT sample set (n=31) (Table 
2 and Figure 3A-C in I; see also Figure 8 for 
a schematic presentation of how the gain of 
EWSR1-FLI1 fusion gene occurs). Two of 
these patients (D153 and D248), whose RNA 
was available for RT-PCR studies, displayed 
EWSR1-FLI1 translocations giving support 
to our array CGH results. Interestingly, also 
two patients with EWSR1-FLI1 translocation 
type 1 (D312 and D315) showed copy number 
changes around the breakpoints of this fusion 
gene (Table 2 in I). However, these samples 
were from metastases, and therefore the ad-
ditional copy number changes might have 
accumulated after the initial diagnosis. On the 
whole, these observations of fusion gene du-
plication arise the question whether the event 
is common in ESFT and how it may affect 
the patient outcome. Duplication of EWSR1-
FLI1 fusion gene can increase its expression, 
promote tumor growth, and subsequently 
lead to poor survival. In ALL, amplification 
of NUP214-ABL1 fusion gene on episomes 
has been shown to account for more aggres-
sive course of disease (graux et al., 2004). 
In lymphomas, amplifications of IGH-MYC 
fusion have been shown to associate with 
rapidly progressing disease and fatal outcome 
(martin-subero et al., 2005). In sarcomas, 
amplifications of PAX-FKHR fusion have 
been found in alveolar rhabdomyosarcoma 
Figure 8. Duplication of derivative chromosome 22 leading to increase in copy number of EWSR1-FLI1 fusion gene. 
Translocation between chromosomes 11 and 22 results in chimeric gene fusion between EWSR1 (at 22q12.1) and FLI1 (at 
11q24.3) gene sequences on derivative chromosome 22. The putative second step, seen in three samples of our patient cohort, 
is the duplication of derivative chromosome 22, which also leads to the duplication of fusion gene EWSR1-FLI1.
45
(weber-hall et al., 1996) and amplifications 
of COL1A1-PDGFB in dermatofibrosarcoma 
(gisselsson et al., 1998), but no associa-
tion with poor survival has been reported so 
far. Because gained EWSR1-FLI1 fusions 
were present in only three of our patients, the 
statistical power of the results was too weak 
to resolve the clinical significance of EWSR1-
FLI1 copy number gains to patient survival. 
Larger studies are warranted to elucidate this 
aspect in EFTS.
Our patient cohort included a 19-year 
old male (D154) with classical Ewing sarcoma 
in humerus with diagnostic and histological 
characteristics of ESFT. RT-PCR analysis 
was not able to detect common EWSR1-FLI1 
or EWSR1-ERG translocations in his clinical 
sample. However, array CGH analysis revealed 
cryptic amplifications of equal magnitude on 
chromosomes 20 and 22, with a breakpoint 
inside the EWSR1 locus at 22q12.1, indicating 
that EWSR1 might have translocated to 
20, which could then have been followed by 
amplification of a novel fusion gene (Figure 
3E-G in I). In a clinical EFTS sample, 
equivalent high-level amplifications on 
chromosomes 20 and 22 have been described 
previously (szuhai et al., 2007), suggesting 
that both of these areas are involved in a 
novel ESFT-specific translocation between 
chromosomes 20 and 22. To study these 
cryptic amplifications in more detail, a higher 
resolution array CGH analysis on 244K 
Agilent platform was performed (Savola et 
al., 2009 unpublished results) (see the 
results in Figure 9). This experiment enabled us 
to study the specific amplification breakpoints 
at chromosome 20 and the genes involved in 
these areas. Interestingly, no ETS gene family 
members are located on chromosome 20, 
which in this case rules out the possibility that 
EWSR1 would be fused with an ETS gene 
family member. The most interesting genes 
pinpointed at amplification breakpoints were 
EYA2 (at 20q13.12) and NFATC2 (at 20q13.2), 
since both of them code for proteins involved 
in transcription regulation (macian et al., 
2001; zhang et al., 2005) and, moreover, 
the manner in which both of the genes were 
oriented at amplification breakpoints makes 
in-frame fusions conceivable. In order to 
confirm the putative fusion gene, RT-PCR 
was applied to detect EWSR1-NFATC2 and 
EWSR1-EYA2 fusion transcripts. However, 
before definitive results of our RT-PCR 
analysis were available, observation of a novel 
EWSR1-NFATC2 fusion gene between exon 
8 of the EWSR1 gene and exon 3 of NFATC2 
in four clinical ESFT samples was published 
(szuhai et al., 2009). Accordingly, this 
finding and our observation suggest that non-
ETS fusions are involved in ESFT. On the 
other hand, this novel fusion gene follows the 
rules of previous EWSR1 fusions, in which the 
RNA binding domain of the EWSR1 gene is 
lost. Interestingly, our high-resolution array 
analysis suggested that the clinical sample 
harbors a putative variant fusion, since EWSR1 
exon 5 seems to have fused to NFATC2 exon 3 
(savola et al., 2009 unpublished results). 
These array CGH results require additional 
studies and need be confirmed using other 
methods like RT-PCR. Particularly, this novel 
fusion gene is of immunological interest, since 
it connects a gene involved in immune response 
to oncologic behavior. Previously NFATC2 has 
been shown to play a significant role in T-cell 
differentiation, immune response, allergies, 
and AIDS (macian, 2005).
Although gene expression levels in 
ESFT have previously been analyzed quite 
extensively (e.g., (cheung et al., 2007; 
schaefer et al., 2008)), the connection 
between gene copy number and expression 
in this disease is poorly understood. Our 
combined bioinformatic analysis, integrating 
data from both DNA and RNA level, revealed 
20 putative oncogenes and tumor suppressor 
genes (q-value <0.20), which have previously 
not been associated with ESFT (Table 3 in 
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Figure 9. Cryptic amplifications detected by high-resolution array CGH on chromosomes 20 and 22 in clinical sample D154. 
Detected amplifications on chromosomes 20 and 22 suggest occurrence of a novel translocation between EWSR1 (at 
22q12.1) and fusion partner at 20q11.23-q13.2, and subsequent amplification of fusion sequences. The genes in amplification 
breakpoints at 20q11.23-q13.2 are RPN2, BLCAP, C2orf100, SLC13A3, EYA2, NCO3, PRX1, Kua-UEV, and NFATC2.
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I). Integration analysis of copy number and 
expression data showed that patients with 
HDGF gain had higher HDGF expression 
(Figure 4A±C  in I) than patients without the 
gain (correlation >0.8). This result was further 
studied by TaqMan RT-PCR analysis, which 
confirmed that ESFT patient samples express 
higher levels of HDGF than normal controls 
(Figure 4D in I), but that elevated expression 
has no effect on survival (Figure 4E-F in I). 
These results suggest that HDGF can have a 
role in tumorigenesis and tumor progression, 
but no prognostic value in ESFT. Previous 
studies have shown that loss of 16q is a sign 
of poor prognosis in ESFT (hattinger et 
al., 1999; ozaki et al., 2001). Two of the 
genes pinpointed in our combined bioinfor-
matic analysis, HEATR3 (at 16q12.1) and 
ANKRD11 (at 16q24.3), showed high correla-
tion of low copy number together with low gene 
expression, suggesting that one of these genes 
could be the target in 16q-deletion, which is 
frequent in ESFT patient samples. Of interest 
is that ANKRD11 (16q24.3) has recently been 
identified to interact with p53 and function as 
a co-activator in the regulatory feedback loop 
(neilsen et al., 2008). However, survival 
analysis according to ANKRD11 expression 
did not show any correlation with patient out-
come in ESFT (savola et al., 2009, unpub-
lished results). Overall, our bioinformatic 
analysis identified several genes in the areas 
of common copy number changes in ESFT. 
These potential ESFT biomarkers can serve as 
a useful resource for future sequencing, clon-
ing, or biologic studies.
9 Inflammatory microenvironment 
in ESFTs (Study II) 
The role of immune system activation in 
tumor progression has been poorly studied in 
ESFTs, although stimulated immune response 
could eradicate minimal residual disease and 
Figure 10. Experimental design in inflammatory gene expression profiling. 
Normal skeletal muscle tissue samples provide a coherent control for expression studies of ESFT tumors, since these tumors 
often develop in close contact with muscle tissue. Additionally, comparison of ESFT patient samples with ESFT cell lines 
provides an excellent opportunity to study inflammatory reactions, since cell lines have no ongoing inflammatory reactions, 
but oncogenic cellular functions in cell lines and tumor cells of patient samples are similar. Obviously, no stromal cells are 
present in cell line samples.
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significantly improve the disease-free and 
long-term survival rates of ESFT patients. Our 
interest was to characterize the inflammatory 
signals that ESFTs produce locally to their 
surrounding tissues. We decided to perform 
a bioinformatic analysis of the expression 
profiles of ESFT patient samples and compare 
the results with the expression profiles of 
normal skeletal muscle tissues and ESFT cell 
lines (Figure 10).
The first question was whether our 
expression and bioinformatic analysis could 
detect inflammatory gene activation in ESFT 
patient samples. When inflammatory gene ex-
pression was compared between ESFT patient 
samples (n=44) and cell lines (n=11), we could 
conclude that inflammatory component was 
activated in ESFT with statistical significance. 
This was based on the following observations: 
(1) The number of upregulated inflamma-
tory genes was 38 of 238 (16%) when 18 was 
expected (p<0.001), and (2) similarly, the 
number of downregulated inflammatory genes 
was 10 of 238 (4%) when 26 was expected 
(p<0.001) (Figure 11). Statistically significant 
upregulation of inflammatory genes in ESFT 
challenges the concept that inflammatory 
microenvironment may not be observed in 
solid pediatric tumors, which may even be re-
garded as developmental disorders (scotting 
et al., 2005). 
Our second question was how this in-
flammatory gene activation is characterized in 
Ewing sarcoma. For this purpose a macrophage 
gene expression signature, including 299 
genes, was extracted from SymAtlas, a publicly 
available data source (su et al., 2002). The 
expression of these macrophage-related genes 
Figure 11. Activation of inflammatory component, most probably characterized by macrophage gene expression, was 
shown with statistical significance in ESFT.
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was compared between ESFT patient samples 
and cell lines. The analysis showed that 58 of 
the 299 (19%) macrophage-related genes were 
upregulated when the expected number was 
23 (p<0.001) (Figure 11). Furthermore, 11 of 
the 299 (4%) macrophage-related genes were 
downregulated when the expected number was 
33 (p<0.001) (Figure 11). These results suggest 
that the inflammatory component in ESFT is 
characterized by statistically significant mac-
rophage gene activation. These observations 
are supported by previous immunohistochemi-
cal results, which show that pediatric cancers, 
including ESFT, are predominantly infiltrated 
by macrophages (vakkila et al., 2006). The 
limitation of our study is that it does not 
provide novel information on the function of 
these macrophages in ESFT microenviron-
ment. Macrophages are known to be involved 
in tumor progression by promoting angiogen-
esis and tumor growth, as well as by inflicting 
immunosuppression (coffelt et al., 2009). 
However, recent studies suggest that TAMs 
present in ESFT microenvironment might 
differentiate to osteoclasts by RANKL- and 
TNF-α-dependent mechanisms, and thereby 
participate in bone resorption as a pathogenic 
mechanism of tumor osteolysis instead of 
taking part in promoting tumorigenesis (lau 
et al., 2007). 
We also used bioinformatic analysis in 
an attempt to detect signs of activated adap-
tive immune reactions in ESFT patients, but 
no significant enrichment of differentially 
expressed genes in different inflammatory 
response phases was found (savola et al., 
2009, unpublished data). However, this 
might not reflect the actual situation in 
ESFT, since the bioinformatic analysis of 
expression profiles across all ESFT patient 
samples might not be the optimal method to 
identify various time-related phases or types 
of inflammatory reactions. A recent study 
showed that immunosuppressive regulatory T 
cells (CD4+CD25hiFoxP3+) in bone marrow 
are detected at significantly higher frequency 
in ESFT patients with metastasis at time 
of diagnosis than in patients with localized 
ESFT (brinkrolf et al., 2009). Interestingly, 
human leukocyte antigen (HLA) class I 
and II expression has also been shown to be 
completely absent or significantly downregu-
lated in the majority of ESFT patient samples 
(berghuis et al., 2009).  These results suggest 
that immune escape mechanisms in ESFT 
might provide means for tumor progression 
and metastatic spread. More extensive stud-
ies to elucidate the role of adaptive immune 
system suppression or activation in ESFT are 
warranted.
Next, we performed a bioinformatic 
analysis using Gene Expression Omnibus 
(GEO) to compare inflammatory genes in 
ESFT patient samples (n=44) and normal 
skeletal muscle tissue samples (n=18) to in-
vestigate how many and which inflammatory 
genes are differentially expressed in this com-
parison. Normal skeletal muscle tissue was the 
selected counterpart because ESFT tumors 
develop in close contact with muscle tissue. 
Secondly, there is no “normal” counterpart to 
ESFT and these tumors have actually been 
suggested to originate from mesenchymal cells 
(tirode et al., 2007; potikyan et al., 2008). 
The final reason was that gene expression in 
bone is difficult to measure due to its mineral-
ized nature and, subsequently, viable cells are 
rare. The results of our bioinformatic analysis 
showed that 32 of 238 (13%) inflammatory 
genes were upregulated and the number of 
downregulated inflammatory genes was 10 of 
238 (4%) when ESFT patient samples were 
compared with normal muscle tissue. 
By combining the lists of differentially 
expressed inflammatory genes in ESFT pa-
tients, cell lines, and normal muscle tissue 
samples, we were able to create two gene lists. 
The first gene list was based on the assump-
tion that the genes, which were upregulated 
in ESFT patients as compared with cell lines 
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samples and also in ESFT patient samples as 
compared with skeletal muscle tissue samples, 
are potentially derived from non-malignant 
infiltrating immune or stromal cells. On the 
other hand, the genes, which were upregulated 
in ESFT patient samples when compared with 
muscle tissue but not when compared with cell 
lines, are putatively derived from malignant 
cells. The list of inflammatory genes derived 
from malignant cells included 22 genes and 
the list of genes derived from non-malignant 
(putatively immune/stromal) cells included 10 
genes (Tables 2 and 3 in II).
Correlation between inflammatory gene 
expression and ESFT patient survival was 
statistically tested using the Kaplan-Meier 
analysis to determine whether the genes pin-
pointed by our bioinformatic analysis have any 
prognostic value in ESFT. High expression of 
JAK1 was shown to correlate with favorable 
overall survival (p=0.04) and high expres-
sion of IL8 resulted in poor overall survival 
in Ewing sarcoma (p=0.04) (Figure 2 in II). 
However, the most interesting result from the 
analysis was that high local expression of C5 
was associated with significantly better event-
free survival (p=0.013) and overall survival 
(p=0.004) across all ESFT patients (n=44) 
in dose dependent manner (Figure 2 in II). 
To our knowledge, this is the first report that 
shows C5 as a predictive marker in any hu-
man cancer. The clinical value of complement 
system activation and the role of C5 in human 
cancers has so far been more or less over-
looked. However, as the complement system 
is able to efficiently activate acute inflamma-
tory responses, the effects of C5 and its active 
subcomponent C5a are of particular interest in 
tumor microenvironment.  C5a is a powerful 
anaphylatoxin, which can recruit a variety 
of C5aR1 receptor-expressing cells. Because 
C5aR1 receptors are frequently expressed 
in various leukocytes, C5a can function as a 
chemoattractant for them (fernandez et al., 
1978). Our immunohistochemical analysis 
of C5 and C5aR1 on ESFT tumor tissue 
microarray verified their expression in ESFT 
cells (Figure 3 in II). Thus, our observations 
suggest that C5 expression and complement 
system activation could have an important role 
in ESFT tumor biology and be a prognostic 
predictor for ESFT patients.
10 CDKN2A deletions in ESFT and ALL 
(Studies III and IV) 
Deletion of 9p21.3, encompassing CDKN2A, 
seems to be a sign of aggressive behavior in 
several cancers, including ESFT and ALL. 
Our array CGH analysis aimed to decipher the 
prevalence and size of these 9p21.3 deletions 
in ESFT and ALL in order to provide novel 
information for assigning patients to a high-
risk group and for developing a novel, more 
reliable and accurate diagnostic method for 
detection CDKN2A deletions. 
Detection of 9p21.3 deletions in 6 of 
26 (23%) ESFT patient samples and 8 of 11 
(73%) ESFT cell lines (Table 1 in III) shows 
that this type of mutation is far more promi-
nent in ESFT cell lines than in clinical ESFT 
samples. This might imply that CDKN2A 
deletions in ESFT cell line samples are highly 
beneficial for in vitro culturing. The smallest 
deletion in our ESFT samples was 41 kb in 
size. Previous studies have reported CDKN2A 
alterations in 10-30% of ESFT patients (ko-
var et al., 1997; tsuchiya et al., 2000; wei 
et al., 2000; lopez-guerrero et al., 2001; 
maitra et al., 2001; huang et al., 2005; 
brownhill et al., 2007). CDKN2A altera-
tions are considerably more frequent in ESFT 
cell lines, as the CDKN2A locus is altered in 
~50% of cell lines (kovar et al., 1997; obana 
et al., 2003). Thus our results were well in line 
with previous observations. 
In ALL patient samples, the deletion 
frequency was 46% (25 of 54) and the smallest 
deletion was 25 kb in size (Table 1 in IV). In 
our adolescent ALL patient cohort, CDKN2A 
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Figure 12. Genomic location of 9p21.3 deletions encompassing CDKN2A locus (n=39), arranged by their size, in ESFT 
patients (n=26), ESFT cell lines (n=11) and ALL patient samples (n=54) analyzed in studies III and IV. 
Figure provides a schematic presentation of the deletions in 9p21.2, zoomed to the genomic area covering 21.5-22.3 Mb of 
9p. The smallest overlapping deletion area of 12.2 kb, encompassing sequences of CDKN2A, is marked with light green. The 
most commonly used commercial CDKN2A FISH probe (Vysis p16 FISH probe of ~190kb in size) is marked with orange 
and the genes in the area are colored as follows: green for CDKN2A, red for CDKN2B and violet for MTAP. It is important 
to appreciate that the smallest overlapping area is 12.2kb, whereas the commercial FISH probe covers ~190kb, which explains 
the inaccuracy of this FISH probe in detecting narrow microdeletions of CDKN2A.
deletions were more prevalent in T-ALL 
(63%) when compared with B-cell precursor 
ALL (45%). Our results are supported by 
recent findings according to which the fre-
quency of CDKN2A deletion varies between 
different ALL subtypes, from 21% in B-cell 
precursor ALL to 50% in T-ALL (sulong et 
al., 2009). 
In both ESFT and ALL samples, the 
smallest overlapping region in 9p deletion 
was 12.2 kb and covered the genomic area 
(nucleotides from 21968346 to 21980581) 
that contains CDKN2A sequences (Figure 
12). We observed both heterozygous and 
homozygous CDKN2A deletions and found 
that the latter were more prevalent in both 
ESFT and ALL. As discussed previously in 
literature review, other CDKN2A inactivation 
mechanisms include methylation at the pro-
moter site. In further studies, p16 promoter 
methylation was detected in 12% (2 of 17) of 
the ESFT cell line samples analyzed (savola 
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et al. 2009, unpublished results). By 
contrast, p14 was not methylated in any of the 
ESFT cell lines (savola et al. 2009, unpub-
lished results). Thus, our results showed 
that, instead of methylation, homozygous de-
letions seem to be the principal mechanism for 
CDKN2A inactivation in ESFT, which is also 
supported by previous observations (tsuchiya 
et al., 2000).
Our survival analysis was not able to 
demonstrate any prognostic value of CDKN2A 
deletion in the ALL patient cohort, although 
it showed a trend toward poorer survival for 
ALL patients with the CDKN2A deletion. The 
cumulative event-free and overall survival rates 
of ALL patients with or without the CDKN2A 
deletion were 62% vs. 70% (p=0.34) and 67% 
vs. 76% (p=0.26), respectively (Figure 3 in IV). 
Moreover, ALL patients with the CDKN2A 
deletion had a tendency to be categorized in 
the poor prognosis group (p=0.06). The reports 
about association between CDKN2A deletions 
and poor patient survival in ALL are contro-
versial. Some studies have indicated a clear 
unfavorable effect (heyman et al., 1996; 
carter et al., 2001; dalle et al., 2002), 
whereas others have shown no effect at all 
(van zutven et al., 2005; mirebeau et al., 
2006). In Ewing sarcoma, CDKN2A deletions 
have been shown to be clinically significant, 
as several studies have demonstrated that 
CDKN2A deletions correlate with poor patient 
survival (tsuchiya et al., 2000; wei et al., 
2000; huang et al., 2005). Moreover, a meta-
analysis of 188 ESFT patients has shown 
with higher statistical power that CDKN2A 
alterations are a statistically significant predic-
tor of poor survival (p<0.001) (honoki et al., 
2007). This suggests that loss of CDKN2A 
may facilitate cellular transformation leading 
to more aggressive tumor behavior and rapid 
course of disease in ESFT. 
Accurate detection of CDKN2A dele-
tions in ESFT and ALL, as well as in other 
tumors, is clinically relevant to identify high-
risk patients and thereby provide them with 
more effective treatment at an early stage of 
the disease. As indicated by our studies of 
the IOR-RCH cell line, a microdeletion of 
CDKN2A (~58 kb) inside a more extensive 
gain of 9p resulted in a false negative FISH 
result using the commercial Vysis FISH probe 
(Figures 1 and 3 in III). It its noteworthy that 
all 9p21.3 deletions, detected in both ESFT 
and ALL, harbored sequences of CDKN2A 
locus. In consequence, CDKN2A seems to be 
the principal target gene of this chromosomal 
aberration, although it is often co-deleted with 
the surrounding genes MTAP and CDKN2B, 
or with either one of these genes (see also 
Figure 12). Whereas our studies (III and IV) 
indicated that the majority of 9p21.3 dele-
tions harboring CDKN2A are detectable by 
FISH, they also showed that small (<190-kb) 
microdeletions encompassing the CDKN2A 
locus occur in ESFT at a frequency of 33% 
(2 of 6 deletions detected) and in ALL the 
rate was 32% (8 of 25 deletions detected). This 
suggests that at diagnosis 8% of our ESFT 
patients (2 of 26) and 15% of our ALL pa-
tients (8 of 54) could be underestimated for 
their CDKN2A deletion status using regular 
commercial FISH probes.
In clinical applications, CDKN2A 
deletions are principally detected using com-
mercial FISH probes, which lack accuracy 
due to their coverage range of 150-190 kb. To 
circumvent this deficiency, the FISH probe 
could be reduced to less than 40 kb and the 
fluorescent signal intensified by novel signal 
amplification techniques. FISH analysis with 
a shorter probe could then be performed on 
interphase cells and it would be suitable also 
for monitoring response to treatment and 
relapse of the disease. Another promising 
technique for detecting small CDKN2A dele-
tions is multiplex ligation-dependent probe 
amplification (MLPA) that provides high 
resolution even to exon level (schouten et 
al., 2002). However, PCR-based techniques 
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are problematic in deletion detection when 
samples have normal cell contamination or 
clonal heterogeneity , which is the case in most 
solid cancers. Although DNA microarray 
technology  would provide sufficient resolution, 
it is not applicable in routine diagnostics due 
to its high cost and heavy technology require-
ments. Moreover, in search for residual disease, 
the sensitivity is not adequate enough to dis-
tinguish single cells among hundreds of sample 
cells. Accordingly, the method for CDKN2A 
detection should be highly sensitive, cost ef-
fective, and quantitative. This demand is best 
met by using the FISH technology. Moreover, 
the detection of CDKN2A aberrations using 
a simple and sensitive FISH method would 
serve the development of effective treatment 
modalities not only for ESFT and ALL, but 
also other cancers.
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microarray-based hybridization merges 
high resolution molecular diagnostics with 
traditional chromosome analysis radically 
transforming the field of genetics. We 
applied this approach to studies of genetic 
alterations in ESFTs and in the CDKN2A 
locus. In study I, 20 novel ESFT-associated 
genes were pinpointed by combined array 
CGH and expression analysis. These genes 
serve as a valuable source for future biologic 
studies and development of new treatments. 
In addition, three ESFT patients showed 
interesting chromosomal rearrangements, 
such as der(22)(11;22) duplication, which 
leads to an increase in the copy number of 
EWSR1-FLI1 fusion. Moreover, high-level 
amplifications on chromosomes 20 and 22 
were detected suggesting a translocation 
between these chromosomes. In study II, 
expression array and bioinformatic analyses 
showed that inflammatory gene activation is 
detectable in ESFT patient samples and it is 
characterized by macrophage gene expression. 
Most importantly, ESFT patient samples were 
shown to express certain inflammatory genes, 
e.g., C5, IL8, and JAK1, which are prognostically 
significant and could serve as potential drug 
targets for ESFT. Based on studies III and IV, 
we can conclude that the smallest overlapping 
region of CDKN2A deletion is 12.2 kb in 
both Ewing sarcoma and ALL, and that the 
most widely used commercial CDKN2A 
FISH probe yields false negative results from 
the narrowest microdeletion cases (<190kb). 
Therefore, more accurate methods should be 
developed for detection of deletions in the 
CDKN2A locus.
ESFTs are a heterogeneous group of 
tumors and every ESFT tumor has unique 
genetic properties of its own, as shown by our 
studies. This highlights the importance for 
striving towards personalized medicine to gain 
the best results in ESFT patient therapy. In 
the future, tumors may no longer be classified 
according to their location or histology, but 
instead according to their activated oncogenic 
or inactivated tumor suppressor pathways. 
These differentially activated pathways could 
be analyzed in diagnostic assays and patients 
would be treated accordingly. Although the 
potential for use of molecular biology and ge-
netics in the diagnostics and management of 
ESFT patients is enormous, large-scale clinical 
trials are urgently needed to assess the reliabil-
ity of these strategies in a clinical setting. 
The remarkable progress that has been 
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seen in ESFT patient survival over the past 
few decades was achieved by multimodal-
ity regimens developed in carefully controlled 
clinical trials. While ESFT patient manage-
ment has advanced to a certain level, we are 
looking forward to the effect of innovative 
therapies based upon novel biologic insights. 
Since the molecular characterization of 
EWSR1-FLI1 fusion in the 90s, this fusion 
gene has been considered to be the ideal target 
for future treatment strategies in ESFT. This is 
because EWSR1-FLI1 fusion is present exclu-
sively in ESFT cells, which makes it a unique 
target protein for molecular therapy. Small 
interfering RNAs (siRNAs) and antisense 
oligonucleotides have performed successfully 
in in vitro settings (ouchida et al., 1995; 
kovar et al., 1996; toretsky et al., 1997). 
Unfortunately, in spite of the great potential 
and encouraging results from these studies, 
pharmacological usage of siRNAs and anti-
sense oligonucleotides has been less successful 
due to difficulties in delivering the drug into 
the tumor and the instability of these nucleic 
acid molecules. ESWR1-FLI1 is still a perfect 
target molecule without a matching thera-
peutic agent in ESFT patient management. 
However, targeted drugs against this fusion 
gene are continually in experimental develop-
ment and approaches using small molecules or 
peptides against ESWR1-FLI1 are currently 
investigated. A recent study showed that a 
small molecule, YK-4-279, was efficiently able 
to block interaction between ESWR1-FLI1 
and RNA helicase A (RHA) and to induce 
apoptosis of ESFT cells (erkizan et al., 
2009). Previously RHA has been shown to 
enhance EWSR1-FLI1 activity and stimulate 
transcriptional activity of EWSR1-FLI1 regu-
lated promoters in ESFT cells, suggesting that 
RHA is necessary for the  oncogenic function 
of EWSR1-FLI1 (toretsky et al., 2006). 
Although immunotherapeutic approaches in 
Ewing sarcoma are still in infancy and remain 
primarily experimental, they have shown 
promising results, as indicated by a recent 
trial with consolidative immunotherapy using 
autologous T cells and dendritic cells pulsed 
with vaccine peptides on recurrent and meta-
static ESFT patients (mackall et al., 2008). 
Another challenge is to identify agents, which 
can reverse the high degree of EFST chemore-
sistance. The first clues towards overcoming 
this impediment were recently published by 
Scotlandi et al., who suggested that glutathione 
metabolism pathway has prognostic significance 
and is the major regulator of ESFT chemore-
sistance (scotlandi et al., 2009). Hopefully, 
inactivation of this pathway or any of the previ-
ously mentioned strategies will prove to be an 
effective means to combat ESFT. 
At present, the public health expendi-
ture to cancer treatment, in Finland as well as 
worldwide, is multifold when compared with 
financial resources used in the cancer diag-
nostics. Nevertheless, it is alarming that some 
cancer patients receive high-priced therapeu-
tic drugs, which may be ineffective in their 
particular type of tumor. Genetic markers and 
molecular diagnostics could help in efforts to 
overcome this obstacle. Similarly, when prog-
nostic biomarkers are not applied efficiently 
enough to cancer diagnostics, patients with 
favorable prognosis receive intensive therapies 
when milder treatment would lead to a bet-
ter result without unpleasant side effects and 
secondary malignancies. Prognostic markers 
like CDKN2A, or C5, which was identified in 
this study (II), could therefore be used more 
efficiently in clinical diagnostics and provide a 
better outlook for cancer patient management. 
The use of microarrays for detecting 
diagnostic and prognostic biomarkers or 
signatures holds great promise in diagnostic 
applications. However, considerable technical 
optimization, platform adjustments (most 
likely in the form of customized arrays), and 
adequate validation procedures are needed. 
Admittedly, the current array methods are well 
suited for research purposes, but in diagnostic 
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applications their massive output of uninfor-
mative data can suppress the bits that would 
be vital in differential diagnostics or prognos-
tic prediction. More robust and rigorous data 
analysis methods should also be developed to 
ease the interpretation of data. 
The development of sequencing 
 methods has proceeded in gigantic steps over 
the past decades and the true achievement has 
been the sequencing of the human  genome 
(lander et al., 2001; venter et al., 2001). 
The speed of genome-wide analysis has 
 increased, the costs per sample have  decreased, 
and sequencing technology has  become more 
affordable. The sequencing-based  molecular 
genetic techniques might therefore become 
more  important and more widely used both in 
research and diagnostic purposes. Ultimately, 
it is likely that sequencing-based  technology 
can replace some of the  cytogenetic  methods 
in the future, because in addition to  detection 
of copy number imbalances also point 
 mutations (substitutions, deletions, and 
inversions) and genome-wide structural 
changes can be  characterized  simultaneously. 
Despite the high resolution and sensitivity for 
 chromosomal rearrangements that  sequencing 
methods  provide,  epigenetic alterations 
 involved in  tumor biology are not deciphered 
by sequencing . However, as known, epigenetic 
alterations play an essential role in tumori-
genesis and belong to the earliest events in 
 different solid tumors. Therefore also epige-
netic changes, like alterations in DNA methy-
lation or histone modification, and differences 
in miRNA  expression, should be analyzed to 
obtain a more complete picture of the complex 
networks involved in ESFT tumorigenesis. 
Moreover, as ESFT is an uncommon disease, 
continuous efforts should be made to join the 
endeavors of  different groups and scientists to 
collect  statistically adequate sample sets and 
clinical data in order to get correct answers to 
clinically important questions and, ultimately, 
to transfer the knowledge gained from in vivo 
and in vitro studies to effective novel thera-
peutic strategies.
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Allele
One of the variant forms of a gene at a particular locus. 
Two alleles of each gene are present in normal genome. 
Anaphylatoxin
Fragment, like C3a or C5a, produced during activation 
of the complement system. Anaphylatoxin is a 
powerful inflammatory mediator able to produce local 
inflammatory response.
Angiogenesis
The formation of new microvessels from pre-existing 
blood vessels.
Apoptosis
Programmed cell death, which is organism’s normal 
method of disposing damaged, unwanted or unneeded 
cells in coordinated manner.
Bacterial artificial chromosome (BAC)
Large segments of DNA, from 100 kb to 200 kb, from 
another species cloned into bacteria. 
Chemokines
Chemotactic cytokines, which are released by infected 
or damaged cells to guide migration of target cells.
Copy number variation (CNV)
Segment of DNA, one kilobase to several megabases in 
size, in which copy-number differences have been found 
by comparing genomes of two or more individuals.
Cytokine
Small protein, which has a specific effect on the 
interaction between cells and which can trigger 
inflammation and respond to infection.
Epigenetic modification
Change in DNA or in the chromatin that does not 
change the sequence, but can be inherited to daughter 
cells after cell division.
Exon
The region in gene that contains the code for producing 
messenger RNA and a possible functional protein.
Fibroblast
Cells of connective tissue that synthesize extracellular 
matrix and collagen. Fibroblasts have a prominent role 
in wound healing.
Fusion gene
A hybrid gene formed by translocation, deletion, or 
chromosomal inversion from two previously separate 
genes. 
Gene
The basic unit of heredity, which contains DNA 
sequences encoding a functional product like protein or 
RNA molecule.
Gene expression
The process by which messenger RNAs and 
subsequently proteins are made from the instructions 
encoded in DNA.
Genome
All DNA contained within an organism, which includes 
chromosomes within the nucleus and mitochondrial 
DNA.
Heterozygous deletion
The human genome contains two copies of each allele 
of the gene. In heterozygous deletion one allele from 
either parent is deleted.
Homozygous deletion
In homozygous deletion both alleles of the gene are 
deleted.
Hybridization
Base pairing of two single strands of DNA or RNA 
based on their complementary sequences. 
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Immunohistochemistry
A method for detecting the presence of specific proteins 
or antigens in tissue sections by using antibodies.
Immunotherapy
Treatment of disease by inducing, enhancing or 
suppressing an immune response, e.g. in cancer by 
stimulating the immune system to reject and destroy 
tumors.
Interphase
The phase of the cell cycle in which the cell spends the 
majority of its time and performs preparations for cell 
division.
In silico
Studies performed on computer or via computer 
simulation.
In vitro
Studies performed outside a living organism such as in 
a laboratory.
Locus
The place on a chromosome where a specific gene is 
located.
Loss of heterozygosity (LOH)
Loss of heterozygosity is a form of allelic imbalance 
that can result from complete loss of an allele or from 
an increase in copy number of one allele relative to the 
other.
Metaphase
The phase of cell division (also called mitosis), when the 
highly condensed chromosomes align along the center 
of the cell.
Metastasis
Spreading of malignant tumor cells beyond the area of 
the original tumor and even to distant locations of the 
body. 
Microarray
A collection of probes arrayed on a glass slide or other 
solid support to assay the presence of complementary 
DNA present in sample of interest.
Mutation
A heritable change in DNA sequence, e.g., point 
mutation, deletion, or structural change.
Necrosis
Uncontrolled death of cells caused by external factors 
like infection or lack of blood flow and oxygen.
Oncogene
Gene, which plays a role in normal cell function, but 
which can be altered genetically thereafter contributing 
to the malignant transformation and the development 
of cancer. Many oncogenes are involved, directly or 
indirectly, in controlling the rate of cell growth.
Polymerase chain reaction (PCR)
A laboratory technique to amplify DNA sequences 
using a specific DNA replication enzyme and short 
DNA sequences called primers to select the portion of 
the genome to be amplified.
Promoter
A DNA sequence, which contains binding site for 
RNA polymerase to initiate transcription of a particular 
gene.
Sarcoma
Tumor derived from connective tissue cells (from 
mesenchymal cells).
Sequencing
Determining the exact order of the base pairs (A, T, C, 
and G) in a fragment of DNA.
Single nucleotide polymorphism (SNP)
DNA sequence variation in which a single nucleotide 
(A, T, C, and G) in the genome differs between two 
individuals of the same species.
Stroma
Cells and connective tissue, which form the supportive 
framework of a tissue or organ.
Transcription factor 
A protein that binds to DNA sequences, e.g., on a 
promoter, to control initiation of transcription.
Tumor suppressor gene
Gene encoding a protein that controls cell cycle and 
inhibits cell division when conditions of growth are not 
met. 
Uniparental disomy (UPD)
In uniparental disomy both copies of alleles or 
chromosome pairs originate from the same parent, 
either maternally or paternally.
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